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I. INTRODUCTION 
There are approximately 50,000 new HIV infections in the United 
States every year.1  While the overall frequency of new, diagnosed, and 
undiagnosed HIV infections—known as “HIV incidence”—has remained 
relatively unchanged, HIV incidence among certain high-risk groups has 
actually increased despite nearly thirty years of condom messaging.2  For 
example, from 2008 to 2010, HIV incidence among men who have sex 
with men (MSM3) increased twelve percent in the United States.4  The 
federal government acknowledges that it has failed to make any 
significant progress toward reducing sexual risk among certain high-risk 
populations, particularly MSM.5  In fact, the Centers for Disease Control 
and Prevention (CDC) found, as of 2013, no change or potential 
movement away from targeted decreases in risk reduction among high-
prevalence groups.6  Research and anecdotal evidence tells us that as 
perceptions about HIV mortality are evolving, traditional approaches to 
HIV prevention rooted in education, behavioral modification, and risk 
reduction are becoming less effective strategies.7  In the words of HIV/
1.  CTRS. FOR DISEASE CONTROL AND PREVENTION, PREEXPOSURE PROPHYLAXIS
FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES–2014: A CLINICAL
PRACTICE GUIDELINE 13 (2014) [hereinafter CDC GUIDELINES], http://www.cdc.gov/ 
hiv/pdf/PrEPguidelines2014.pdf [http://perma.cc/P8YN-NB9M]; HIV in the United 
States: At a Glance, CENTERS FOR DISEASE CONTROL & PREVENTION, http://www.cdc. 
gov/hiv/statistics/basics/ataglance.html [http://perma.cc/NDS6-PK93] (last updated Nov. 
25, 2014). 
2.  See HIV Incidence, CENTERS FOR DISEASE CONTROL & PREVENTION, http://
www.cdc.gov/hiv/statistics/surveillance/incidence/index.html [http://perma.cc/76BS-ZGGW] 
(last updated May 22, 2013). 
3. For the purpose of this Article, MSM includes any man who has sex with
another man; this high-prevalence group includes those who self-identify as homosexual, 
heterosexual, bisexual, and transgender.  See Policy Brief: HIV and Sex Between Men, 
UNAIDS 1 (Aug. 2006), http://data.unaids.org/pub/BriefingNote/2006/20060801_policy 
_brief_msm_en.pdf [http://perma.cc/U22P-RDVV] (noting that the umbrella term MSM 
“encompasses a range of sexual and gender identities among people in various sociocultural 
contexts”). 
4.  HIV in the United States: At a Glance, supra note 1 (stating that the estimated
number of new HIV infections among MSM increased from 26,700 in 2008 to 29,800 in 
2010); see also CTRS. FOR DISEASE CONTROL & PREVENTION, NATIONAL HIV PREVENTION 
PROGRESS REPORT, 2013, at 17 (2013) [hereinafter PROGRESS REPORT], http://www. 
cdc.gov/hiv/pdf/policies_NationalProgressReport.pdf [http://perma.cc/HNH5-KHRZ] (finding 
that unchanged risk behavior among MSM from 2008 to 2011 coupled with increasing 
numbers of new HIV infections among MSM is “especially worrisome”). 
5.  See PROGRESS REPORT, supra note 4, at 2.
6.  See id.
7.  See, e.g., Junjun Jiang et al., Pre-Exposure Prophylaxis for the Prevention of
HIV Infection in High Risk Populations: A Meta-Analysis of Randomized Controlled 
Trials, PLOS ONE 1 (Feb. 3, 2014), http://www.plosone.org/article/fetchObject.action? 
uri=info%3Adoi%2F10.1371%2Fjournal.pone.0087674&representation=PDF [http://perma.cc/ 
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AIDS activist Peter Staley: “Because we don’t have the death and dying 
that forced a drastic change in sexual behavior . . . in the mid-‘80s, which 
was largely sustained until the early ‘90s, the safe-sex condom code that 
we created then has collapsed.”8 
Abandoning condom advocacy is not the answer for the majority of 
HIV/AIDS advocates.9  Reducing condomless sex—the primary route of 
HIV transmission10—continues to be a priority in HIV prevention and in 
the prevention of other sexually transmitted infections.11  However, 
attention has rapidly shifted to developing new HIV prevention modalities 
and to integrating these new modalities into more traditional prevention 
CBN5-LQCD] (finding that “[t]raditional interventions have been known to be poorly 
effective in HIV prevention”); Mary Jane Rotheram-Borus et al., The Past, Present, and 
Future of HIV Prevention: Integrating Behavioral, Biomedical, and Structural Intervention 
Strategies for the Next Generation of HIV Prevention, 5 ANN. REV. CLINICAL PSYCHOL. 
143, 149 (2009) (stating that although barrier methods such as condom usage can reduce 
HIV incidence by as much as ninety-five percent, “most persons do not use condoms 
consistently or correctly, so effectiveness falls to about 70%” (citing Anna F. Foss et al., 
Condoms and Prevention of HIV Are Essential and Effective but Additional Methods Are 
Also Needed, 329 BMJ 185, 185 (2004))); see also Andrew M. Seaman, Men at High Risk 
for HIV May Misjudge Their Vulnerability, REUTERS (June 26, 2014, 12:07 PM), 
http://www.reuters.com/article/2014/06/26/us-gay-men-hiv-truvada-idUSKBN0F12012 
0140626 [http://perma.cc/SR8P-9MH3] (discussing a recent study finding decreased 
perception of HIV risk in MSM attending bathhouses and sex clubs). 
8. Mark Joseph Stern, “I Have Learned Not to Underestimate the Stigma”: Peter
Staley on Truvada, Condoms, and HIV Prevention, SLATE (May 22, 2014, 9:00 AM), 
http://www.slate.com/blogs/outward/2014/05/22/peter_staley_talks_about_truvada_hiv_
and_stigma.html [http://perma.cc/WV69-8LKR]. 
9. In this Article, I am not suggesting that condom advocacy is not a wise use of
resources in light of declining usage trends.  I seek to investigate the challenges that will 
shape the scaling up of HIV pre-exposure prophylaxis as a second and third line of defense 
in combination with condoms and behavioral interventions.  See Sunnivie Brydum, Is 
PrEP the End of HIV in the U.S.?, ADVOCATE (Oct. 30, 2014, 7:00 AM), 
http://www.advocate.com/31-days-prep/2014/10/30/prep-end-hiv-us [http://perma.cc/JE6E- 
Y3L5] (noting that “most doctors and activists—in addition to overarching agencies like 
the Centers for Disease Control and Prevention and the World Health Organization—urge 
that PrEP be used in conjunction with existing strategies”).  I also seek to investigate these 
challenges in the context of individuals who use PrEP as a primary means of HIV 
prevention in lieu of condoms. 
10.  See Who’s at Risk for HIV, CENTERS FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/hiv/risk/index.html [http://perma.cc/D5B2-FAMA] (last updated Oct. 30, 
2014). 
11.  See PROGRESS REPORT, supra note 4, at 17 (stating that although “the majority
of MSM have tried to lower their HIV risk,” there remains “an urgent need to improve the 
effectiveness of HIV prevention efforts” for MSM and other high-risk populations). 
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models.12  Antiretroviral drugs (ARVs), which were introduced to suppress 
the virus in HIV-positive individuals, are now being used as a 
pharmacological prevention modality for HIV-negative individuals.13  In 
pharmacological prevention, medication is prescribed to someone with 
specific risk factors for an illness that has not occurred or is asymptomatic. 
Pharmacological preventions are by no means new in the medical 
community.14  Examples of well-established, FDA-approved pharmacological 
preventions include the prescription of statin therapy to diabetics who are 
at risk of developing cardiovascular disease,15 Malarone for the prevention of 
Malaria,16 and contraceptives to prevent pregnancy.17 
In the context of HIV prevention, however, pharmacological prevention 
is newer to the market.  Oral HIV pre-exposure prophylactic medication, 
known as PrEP or oral PrEP,18 typically consisting of single or compound 
ARVs taken by HIV-negative individuals in advance of potential 
exposure, has been the subject of a deluge of media, public health, and 
regulatory attention in light of multiple trials showing it significantly 
reduces the risk of infection.19  The FDA recently approved the use of an 
12.  See Rotheram-Borus et al., supra note 7, at 150.
13.  See PrEP for HIV Prevention, CENTERS FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/features/stop-hiv-prep [http://perma.cc/EPY4-AKCY] (last updated 
May 14, 2014). 
14.  See Diane Anderson-Minshall, Ask a Doctor: What’s Stopping Us from Talking 
About PrEP?, ADVOCATE (Oct. 31, 2014, 3:00 AM), http://www.advocate.com/31-days-
prep/2014/10/31/ask-doctor-whats-stopping-us-talking-about-prep [http://perma.cc/94D6-VYUX] 
(“PrEP itself is not exclusive to HIV. . . .  We do PrEP for many other diseases.”). 
15.  See Am. Diabetes Ass’n, Standards of Medical Care in Diabetes—2013, 36
DIABETES CARE S11, S31, S34 (2013), http://care.diabetesjournals.org/content/36/Supplement 
_1/S11.full.pdf [http://perma.cc/PP54-HBTR]. 
16.  See Medicines for the Prevention of Malaria While Traveling: Atovaquone-
Proguanil (Malarone™), CENTERS FOR DISEASE CONTROL & PREVENTION, http:// 
www.cdc.gov/malaria/resources/pdf/fsp/drugs/atovaquoneproguanil.pdf [http://perma.cc/ 
Y6QZ-HB4Y] (last visited Mar. 25, 2015). 
17.  See Estrogen and Progestin (Oral Contraceptives), MEDLINEPLUS, http://www.
nlm.nih.gov/medlineplus/druginfo/meds/a601050.html [https://perma.cc/VAW2-PY8S?type= 
image] (last updated Jan. 26, 2015). 
18. Barrier treatments such as condoms are technically a kind of PrEP, as they
preventatively reduce the risk of HIV exposure.  See Rotheram-Borus et al., supra note 7, 
at 148–49.  However, the media, public health officials, and HIV/AIDS advocacy 
organizations have requisitioned the acronym PrEP to exclusively refer to the use of ARVs 
as preventive treatment.  For the sake of clarity, references to PrEP or oral PrEP in this 
Article refer solely to oral HIV PrEP. 
19.  See, e.g., infra notes 20–25, 54–58, 66, 104, 115; see also Ume L. Abbas et al.,
Antiretroviral Therapy and Pre-Exposure Prophylaxis: Combined Impact on HIV 
Transmission and Drug Resistance in South Africa, 208 J. INFECTIOUS DISEASES 224, 224 
(2013) (noting there is public concern about the potential emergence and spread of HIV 
drug resistance arising from the rollout of ARV as PrEP); Michael C. Thigpen et al., 
Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana, 
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ARV called Truvada®, and the CDC issued final guidance on the matter, 
which has thrust oral PrEP into the spotlight.  Yet, despite evidence of its 
effectiveness and concomitant public health and regulatory responses, oral 
PrEP has proven controversial.20 
PrEP intervention has been the subject of notable dissensus, particularly in 
the lesbian, gay, bisexual, and transgender (LGBT) community.21  For 
example, Larry Kramer, a long-time HIV/AIDS activist, recently stated 
that people taking Truvada for PrEP must have “rocks in their heads” for 
risking potential long-term side effects.22  Controversially, Michael 
Weinstein, President of the AIDS Healthcare Foundation (AHF), 
analogized oral PrEP to a “party drug” and predicted that it would lead to 
widespread drug resistance and encourage condomless intercourse.23  
Conversely, a great number of HIV/AIDS advocacy groups, activists, and 
367 NEW ENG. J. MED. 423, 423–24 (2012) (reporting the transmission of HIV was reduced 
in men who have sex with men who took ARVs daily); PrEP, CENTERS FOR DISEASE 
CONTROL & PREVENTION, http://www.cdc.gov/hiv/basics/prep.html [http://perma. cc/7ZL6-
GMQD] (last updated Jan. 16, 2015) (discussing how PrEP works to prevent the spread of 
HIV in people who are at high risk of contracting the virus). 
20.  See, e.g., Michael Weinstein et al., Discussion: Is PrEP a Good Way to Fight
HIV Infections?, N.Y. TIMES: ROOM FOR DEBATE (June 17, 2014), http://www. 
nytimes.com/roomfordebate/2014/06/17/is-prep-a-good-way-to-fight-hiv-infections [http:// 
perma.cc/X9Z6-H4VR]; Associated Press, Divide over HIV Prevention Drug Truvada 
Persists, USA TODAY (Apr. 6, 2014, 6:28 PM), http://www.usatoday.com/story/ 
news/nation/2014/04/06/gay-men-divided-over-use-of-hiv-prevention-drug/7390879 [http:// 
perma.cc/Z6B7-VMW2] (noting that “[t]he discussion can torch emotions like a flame-
thrower on a fuel depot”). 
21.  Compare Mark Joseph Stern, There Is a Daily Pill That Prevents HIV. Gay Men 
Should Take It., SLATE (Jan. 6, 2014, 12:00 PM), http://www.slate.com/blogs/outward/ 
2014/01/06/truvada_prep_hiv_gay_men_should_take_pre_exposure_prophylaxis.html [http:// 
perma.cc/B78C-QGXS] (advocating for the use of Truvada among the gay population), 
with David Duran, Truvada Whores?, HUFFINGTON POST, http://www.huffingtonpost.com/ 
david-duran/truvada-whores_b_2113588.html [http://perma.cc/2VFP-659A] (last updated Jan. 
12, 2013, 5:12 AM) (arguing “the FDA is encouraging the continuation of unsafe sex and 
most likely contributing to the spread of other sexually transmitted infections”). 
22.  See Patrick Healy, A Lion Still Roars, with Gratitude, N.Y. TIMES (May 21,
2014), http://www.nytimes.com/2014/05/25/arts/television/larry-kramer-lives-to-see-his-
normal-heart-filmed-for-tv.html?r=0 [http://perma.cc/89JR-8XGA]. 
23.  Michelle Garcia, Why Michael Weinstein Gets Blamed for PrEP Myths,
ADVOCATE (Oct. 31, 2014, 9:08 AM), http://www.advocate.com/31-days-prep/2014/ 
10/31/why-michael-weinstein-gets-blamed-prep-myths [http://perma.cc/JTK9-SCSJ]; Curtis 
M. Wong, Robert Levithan, AIDS Activist, on the Use of Controversial HIV Prevention 
Drug Truvada, HUFFINGTON POST, http://www.huffingtonpost.com/2014/ 05/27/robert-
levithan-aids-truvada_n_5399423.html [http://perma.cc/4KYG-JF7W] (last updated May 
27, 2014, 4:59 PM). 
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public health officials have deemed PrEP a necessary safety net, 
particularly given the existence of a sizeable population of individuals 
who continue risk-taking activity notwithstanding behavioral messaging.24  
In the imagination of some PrEP proponents, PrEP has the potential to 
usher in an exciting sexual revolution in which the threat of HIV becomes 
a thing of the past.25  Indeed, those who take oral PrEP have called it “an 
extra layer of protection,” providing “peace of mind” during sexual 
intercourse.26 
The vigorous debate over PrEP prevention was the genesis of this 
Article.  Why has oral PrEP generated so much debate?  What are the 
barriers to fuller implementation of this pharmacological innovation? 
How will the post-health reform landscape affect its implementation? 
Will insurers cover it in the future?  Is use of oral PrEP medically 
necessary?  How should advocacy groups, lawmakers, and policymakers 
act if insurers begin to deny coverage?  Will the U.S. Supreme Court’s 
Burwell v. Hobby Lobby ruling affect future PrEP implementation efforts? 
These are a selection of questions that arose during preliminary research. 
There is considerable literature regarding the impact of The Patient 
Protection and Affordable Care Act (ACA) on access to treatment for 
HIV-positive individuals.27  However, there is little published legal 
scholarship focusing solely on oral PrEP prevention and the post-ACA 
challenges facing those seeking fuller implementation.28  In this Article, I 
24.  Press Release, Leading HIV/AIDS Groups Endorse CDC HIV PrEP
Guidelines: Reiterate That PrEP Is a Powerful, Additional Tool in the AIDS Response 
(June 17, 2014), http://paperzz.com/doc/1169130/leading-hiv-aids-groups-endorse-cdc-
hiv-prep—-prepwatch [http://perma.cc/VF58-UNNK]; Aaron Hicklin, Andrew Sullivan 
Calls Out Larry Kramer on Truvada, OUT (May 27, 2014, 1:58 PM), http://www. 
out.com/entertainment/popnography/2014/05/27/andrew-sullivan-calls-out-larry-kramer-
denigrating-truvada [http://perma.cc/3PQP-5NVS]. 
25. Tim Vollmer & Doug Sebesta, Does PrEP = A New Gay Sexual Revolution?,
BAY AREA REPORTER (July 24, 2014), http://www.ebar.com/openforum/opforum.php? 
sec=guest_op&id=478 [http://perma.cc/5CT7-XDFG]. 
26. Hailey Gilmore, Presentation at 9th International Conference on HIV Treatment
and Prevention Adherence: To PrEP or Not To PrEP: Perspectives from US iPrEx Open 
Label Extension (OLE) Participants (June 9, 2014), http://www.iapac.org/ 
AdherenceConference/presentations/ADH9_OA440.pdf [http://perma.cc/MJJ9-2G8V]. 
27.  See, e.g., Affordable Care Act and Its Impact on People Living with HIV/AIDS,
AIDS ACTION COMMITTEE (Oct. 1, 2013), http://www.aac.org/media/blog/ affordable-care-
act-and-its-impact.html [http://perma.cc/U5YW-SNKW]; see also Jennifer Kates et al., 
Assessing the Impact of the Affordable Care Act on Health Insurance Coverage of People 
with HIV, KAISER FAM. FOUND. (Jan. 7, 2014), http://kff.org/report-section/assessing-the-
impact-of-the-affordable-care-act-on-health-insurance-coverage-of-people-with-hiv-issue-brief 
[http://perma.cc/B5H6-UL3C]. 
28. Kristen Underhill’s comprehensive, impeccably researched article, Paying for
Prevention, pertains to a number of established and emerging biomedical HIV preventions, 
including (1) oral PrEP, (2) oral post-exposure prophylaxis, known as “PEP”, taken by 
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argue that in order to effectively incorporate PrEP into existing prevention 
models and drive down HIV incidence, proponents must overcome 
fundamental social, political, and legal challenges to ensure sustainable 
access for the individuals most at risk.  I suggest that requiring insurers to 
cover PrEP and eliminating some of the barriers to access through federal 
and state action would help resolve acceptability and accessibility barriers 
to wider implementation that proponents have faced, and will likely face, 
in the future. 
In Part II of the Article, I place PrEP in the broader context of HIV 
prevention and details recent regulatory responses to PrEP, including the 
2012 FDA approval of Truvada for PrEP applications and the recent 
impactful CDC guidelines.  In Part III, I introduce a framework for 
approaching the implementation of PrEP by dividing current and anticipated 
challenges into two dimensions: acceptability and accessibility.  I argue 
that the major acceptability challenges involve eliminating stigmas 
associated with PrEP prevention within high-risk communities and changing 
attitudes within the medical community.  This involves eliminating 
self-imposed, individual, and institutional biases.  With regard to 
affordability, I highlight the cost of PrEP treatment, discuss the negative 
effect of prior authorization, and argue that PrEP may be susceptible to 
future coverage denials based on exclusions in benefit policies.  These 
multidimensional accessibility issues have the potential to render this 
already underutilized HIV prevention tool, which is even more inaccessible 
to the people who need it most.  In Part IV, I consider a health content 
regulation solution as one aspect of overcoming these challenges.  I discuss 
options at the federal level under the ACA’s “preventive services” provision 
(PSP) and the possibility of a positive recommendation from the U.S. 
Preventive Services Task Force (USPSTF or Task Force), which could 
mandate PrEP coverage at no cost to the insured.  In addition, I propose 
federal regulatory action in connection with the ACA’s “essential health 
benefits” provision (EHBP), which would help streamline some of the 
barriers to access in the utilization review process.  Finally, I explore the 
possibility of mandated benefit laws at the state level, which could help 
HIV-negative individuals after a suspected exposure, (3) ARV-laden microbial gels for 
vaginal or anal application to prevent infection, (4) male circumcision, and (5) vaccines. 
See Kristen Underhill, Paying for Prevention: Challenges to Health Insurance Coverage 
for Biomedical HIV Prevention in the United States, 38 AM. J.L. & MED. 607, 610 (2012). 
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change attitudes toward, ensure access to, and ultimately achieve greater 
utilization of PrEP prevention. 
II. BACKGROUND
An estimated 1.2 million Americans are living with HIV.29  An HIV 
diagnosis today is by no means the death sentence it was during the early 
years of the AIDS crisis.  HIV is now regarded in the medical and public 
health communities as a chronic manageable disease.30  In the general 
population, the urgency of the HIV/AIDS epidemic has waned.  According 
to a 2009 study, only about six percent of the general public indicated that 
HIV/AIDS was the most urgent health problem facing the nation 
compared to forty-four percent in 1995.31 
Nonetheless, the enduring HIV prevention approach remains rooted in 
the tragic HIV pandemonium of the 1980s.  The model for our current 
message about HIV prevention developed when HIV/AIDS emerged as a 
leading cause of death in the United States.32  In the 1980s, public fear 
surrounding HIV/AIDS was at an all-time high, and HIV was regarded as 
“the most dreaded communicable disease that we know about.”33  By the 
mid-1990s, HIV education and awareness campaigns were ubiquitous and 
seemed to be working.34  HIV prevention experts focused on public health 
29. Ctrs. for Disease Control & Prevention, Vital Signs: HIV Diagnosis, Care, and
Treatment Among Persons Living with HIV—United States, 2011, 63 MORBIDITY &
MORTALITY WKLY. REP. 1113, 1113 (2014), http://www.cdc.gov/mmwr/pdf/wk/mm63 
47.pdf [http://perma.cc/GCN2-S2TJ].
30.  Chronic Manageable Disease, AIDS.GOV., http://www.aids.gov/hiv-aids-basics/
just-diagnosed-with-hiv-aids/overview/chronic-manageable-disease [https://perma.cc/6UQM- 
B4SA?type=image] (last updated Dec. 22, 2009). 
31. KAISER FAMILY FOUNDATION, 2009 SURVEY OF AMERICANS ON HIV/AIDS:
SUMMARY OF FINDINGS ON THE DOMESTIC EPIDEMIC 3 (2009), http://kaiserfamilyfoundation. 
files.wordpress.com/2013/01/7889.pdf [http://perma.cc/4RS8-BS6R]. 
32. Ctrs. for Disease Control & Prevention, Update: Mortality Attributable to HIV
Infection/AIDS Among Persons Aged 25–44 Years—United States, 1990 and 1991, 42
MORBIDITY & MORTALITY WKLY. REP. 481, 481 (1993), http://www.cdc.gov/mmwr/PDF/ 
wk/mm4225.pdf [http://perma.cc/2ZCD-V7JP]. 
33. Images Best Shot, Aids and Montage of 1980s–Part 1, YOUTUBE (Oct. 27,
2010), https://www.youtube.com/watch?v=9oenTf9BUcw [https://perma.cc/E6Q5-VF4D?type= 
live] (statement of James O. Smith, former Superintendent, Western School Corporation).  
Smith’s refusal to permit HIV-positive hemophiliac Ryan White to attend school engendered 
litigation that led to the Ryan White Care Act, which is still very much in force today.  See 
Ryan White HIV/AIDS Treatment Extension Act of 2009, Pub. L. No. 111-87, 123 Stat. 
2885 (2009). 
34.  See Press Release, Ctrs. for Disease Control and Prevention, 1996 HIV/AIDS
Trends Provide Evidence of Success in HIV Prevention and Treatment (Feb. 1996), 
http://www.cdc.gov/media/pressrel/aids-d1.htm [http://perma.cc/EJ36-379U]; A Timeline 
of AIDS, AIDS.GOV, http://www.aids.gov/hiv-aids-basics/hiv-aids-101/aids-timeline 
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awareness and educational campaigns, which emphasized modes of 
transmission, HIV testing and treatment, consistent and proper use of 
condoms and other barrier methods, and risk-reducing behaviors such as 
abstinence and monogamy.35  However, traditional approaches to HIV 
prevention are not keeping up with widespread behavioral changes 
resulting from factors such as the increase in acceptability of condomless 
sex, optimism about HIV/AIDS, and condom message fatigue.36  Biomedical 
prevention—notably oral PrEP—is a much-needed new approach to 
prevention that has re-energized HIV prevention in the United States and 
carried it into the twenty-first century. 
A.  Condoms Today 
Condoms are medically effective at preventing HIV, eliminating 
approximately ninety to ninety-five percent of the transmission risk when 
used properly and vigilantly.37  But this figure misrepresents the actual 
efficacy of condoms in practice.  Indeed, actual efficacy of condoms is 
significantly lower due to improper use, intermittent use, or nonuse.38  
There are a number of studies that, in the aggregate, suggest a startlingly 
lower actual efficacy.  In one New York study, sixty-six percent of adult New 
[https://perma.cc/CRD9-N65P?type=image] (last visited Mar. 25, 2014) (noting that in 
1996, HIV diagnoses “decline[d] for the first time since the beginning of the epidemic”). 
35.  See JULIA DAVIS, KAISER FAMILY FOUND., EVOLUTION OF AN EPIDEMIC: 25 
YEARS OF HIV/AIDS MEDIA CAMPAIGNS IN THE U.S.13–16 (1996), http://kaiser 
familyfoundation.files.wordpress.com/2013/01/7515.pdf [http://perma.cc/XH2L-PPVN]. 
36.  See Stephen F. Morin et al., Why HIV Infections Have Increased Among Men
Who Have Sex with Men and What To Do About It: Findings from California Focus 
Groups, 7 AIDS & BEHAV. 353, 355–56 (2003), http://download.springer.com/static/ 
pdf/293/art%253A10.1023%252FB%253AAIBE.0000004727.23306.20.pdf?auth66=142
4998941_4980abdb78ee0793a0bd485895d5c8f6&ext=.pdf [http://perma.cc/2F3C-H9ZL]; 
Barry D. Adam et al., AIDS Optimism, Condom Fatigue, or Self-Esteem? Explaining 
Unsafe Sex Among Gay and Bisexual Men, 42 J. SEX RES. 238 (2005), http://www.tand 
fonline.com/doi/pdf/10.1080/00224490509552278. 
37. Steven D. Pinkerton & Paul R. Abramson, Effectiveness of Condoms in Preventing 
HIV Transmission, 44 SOC. SCI. & MED. 1303, 1310 (1997). 
38.  Id. at 1304 (noting that meta-analyses of condom effectiveness in practice
suggests sixty to seventy percent effectiveness (citing Susan C. Weller, A Meta-Analysis 
of Condom Effectiveness in Reducing Sexually Transmitted HIV, 36 SOC. SCI. & MED. 
1635, 1640 (1993); Laurie Liskin et al., Condoms—Now More than Ever, POPULATION
REP., Sept. 1990, at 5)); see also supra note 7 and accompanying text. 
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Yorkers surveyed indicated they do not use condoms.39  With regard to 
youth attitudes, a Durex Global Survey in December 2011 found six out 
of ten men and women in the United States did not use any form of 
protection against HIV/AIDS or sexually transmitted infections when they 
lost their virginity.40  Condom usage among American students hit its peak 
at around sixty percent a decade ago.41  However, condom usage in this 
group has stalled since then according to the CDC and a number of recent 
studies.42  In a 2013 study of young African-American MSM, sixty-seven 
percent of study participants indicated they had engaged in unprotected 
receptive anal intercourse in the last six months.43  These studies suggest 
that one cannot judge the legitimacy of new HIV prevention modalities 
by comparing them to the ninety to ninety-five percent effectiveness rate 
of condoms.  After all, fewer people are using condoms properly, and 
more people are eschewing them entirely.44 
Additionally, there is some evidence that increased condom messaging 
through new technologies in response to the decline in condom usage will 
not be sufficient to combat the spread of HIV.45  One study found the 
39.  Carl Campanile, 66% of New Yorkers Don’t Use Condoms: Survey, N.Y. POST
(Oct. 27, 2013, 11:14 PM), http://nypost.com/2013/10/27/one-in-three-nyc-adults-use-
condoms-survey [http://perma.cc/NTB7-PY23]. 
40.  When It Comes to Risky Sexual Behavior, Americans Top the List: Durex Global 
Survey Data Released for World AIDS Day, PR NEWSWIRE (Nov. 30, 2011), http:// 
www.prnewswire.com/news-releases/when-it-comes-to-risky-sexual-behavior-americans-top- 
the-list-134764733.html [http://perma.cc/9K78-MPQD]. 
41. Katy Steinmetz, (No) Condom Culture: Why Teens Aren’t Practicing Safe Sex,
TIME (Nov. 12, 2013), http://healthland.time.com/2013/11/12/no-condom-culture-why-
teens-arent-practicing-safe-sex/?hpt=hp_t3 [http://perma.cc/GD4H-G83L]. 
42.  See, e.g., Ctrs. for Disease Control & Prevention, HIV, Other STD, and
Pregnancy Prevention Education in Public Secondary Schools—45 States, 2008–2010, 
61MORBIDITY & MORTALITY WKLY. REP. 222 (2012), http://www.cdc.gov/mmwr/ 
preview/mmwrhtml/mm6113a2.htm [http://perma.cc/RNN4-ABA2]; M. Lynne Cooper, 
Alcohol Use and Risky Sexual Behavior Among College Students and Youth: Evaluating 
the Evidence, 14 J. STUD. ON ALCOHOL & DRUGS SUPPLEMENT 101, 104 (2002), 
http://www.jsad.com/doi/pdf/10.15288/jsas.2002.s14.101 [http://perma.cc/5GL9-PHEW]; 
Patricia Barthalow Koch et al., Mixing Sex and Alcohol in College: Female-Male HIV Risk 
Model, 24 J. SEX EDUC. & THERAPY 99, 99 (1999). 
43. Richard A. Crosby et al., Acceptability of Condoms, Circumcision and PrEP
Among Young Black Men Who Have Sex with Men: A Descriptive Study Based on 
Effectiveness and Cost, 2 VACCINES 129, 131 (2014), http://www.mdpi.com/2076-
393X/2/1/129/htm [http://perma.cc/F6X3-ZXQ5]. 
44.  See Letter from Janet Woodcock, Dir., Ctr. for Drug Evaluation & Research, to
Tom Myers, Gen. Counsel, AIDS Healthcare Found. (July 16, 2012), http://www. 
regulations.gov/#!documentDetail;D=FDA-2012-P-0226-0006 [http://perma.cc/5HNE-
N3TS] (citing Pinkerton & Abramson, supra note 37, at 1306–07). 
45.  See Brian Mustanski et al., Effects of Messaging About Multiple Biomedical and 
Behavioral HIV Prevention Methods on Intentions To Use Among US MSM: Results of an 
Experimental Messaging Study, 18 AIDS & BEHAV. 1651, 1656 (2014). 
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number of informational messages about condom usage on social media 
neither engenders “differential attitudes and intentions regarding condoms” 
nor changes attitudes about unprotected intercourse.46  Conversely, 
multiple informational messages regarding PrEP did cause increased 
interest in using the new modality.47  Even though consistent and proper 
condom use is medically effective at preventing HIV transmission and 
condom messaging remains an important aspect in the prevention of HIV 
and other sexually transmitted infections,48 we need to develop new 
prevention tools to counterbalance evolving perceptions, disinhibition 
trends, and educational insouciance. 
B.  PrEP: A New Approach to HIV Prevention 
There is a rapidly growing body of research about the effectiveness of 
the combination of behavioral prevention and biomedical prevention. 
One type of biomedical prevention is pharmacological prevention.49  In 
the context of HIV prevention, the discovery of the prophylactic use of 
ARVs occurred during ARV clinical trials in the 1990s.50  Today, 
46.  Id. at 1651.
47.  Id. at 1656.
48.  Condoms and STDs: Fact Sheet for Public Health Personnel, CENTERS FOR
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/condomeffectiveness/docs/Condoms 
_and_STDS.pdf [http://perma.cc/9RKE-E92H] (last visited Mar. 25, 2015); Condom Fact 
Sheet in Brief, CENTERS FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/ 
condomeffectiveness/docs/CondomFactsheetInBrief.pdf [http://perma.cc/X29G-UGN5] (last 
visited Mar. 25, 2015). 
49.  Underhill, supra note 28, at 621.
50.  See Edward M. Connor et al., Reduction of Maternal-Infant Transmission of
Human Immunodeficiency Virus Type 1 with Zidovudine Treatment, 331 NEW ENG. J.
MED. 1173 (1994).  In studies of HIV-positive pregnant woman, those who received ARVs 
had a sixty-eight percent reduction in the risk of perinatal transmission of HIV.  Id. at 
1176.  Infants effectively received both PrEP in utero and PEP treatment for six weeks 
after birth, and the positive results led to further studies of both PrEP and PEP, though 
studies of PEP, particularly as related to occupational exposure, were more prevalent.  Id. 
at 1178.  PEP, however, has not proved as controversial as PrEP.  See David Tuller, A 
Resisted Pill To Prevent H.I.V., N.Y. TIMES, Dec. 30, 2013, http:// www.nytimes.com/2013/ 
12/31/health/a-resisted-pill-to-prevent-hiv.html?pagewanted=all&r=0 [http://perma.cc/Q6LA-
LJWP].  One explanation for this is that whereas PrEP is a daily prophylactic taken in 
perpetuity, PEP is taken for a discrete period of time—approximately one month—so the 
risk of long-term side effects is reduced.  See David T. Kuhar et al., Updated US Public 
Health Service Guidelines for the Management of Occupational Exposures to Human 
Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis, 34 
INFECTION CONTROL & HOSP. EPIDEMIOLOGY 875, 878 (2013) (recommending ARV 
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pharmacological HIV prevention includes but is not limited to the following 
treatments: (1) oral PrEP, (2) oral post-exposure prophylactics, known as 
“PEP,” taken by HIV-negative individuals after a suspected exposure, (3) 
ARV-laden microbial gels for vaginal or anal application to prevent 
infection, (4) ARVs taken by HIV-positive individuals as a means of 
lowering viral load and thereby preventing infection of others, known as 
“treatment as prevention” or “TasP,”51 and (5) vaccines.52 
However, no other pharmacological HIV prevention method has 
exploded onto the clinical research scene like oral PrEP has.  As of this 
writing, there are at least forty clinical studies involving PrEP that are 
enrolling, recruiting, or in progress.53  Four double-blind, placebo-
controlled clinical trials involving Truvada as an oral PrEP in high-risk 
populations have been published.  The first two studied PrEP among MSM.54  
treatment for four weeks in the case of suspected exposures (citing Ctrs. for Disease 
Control & Prevention, Updated U.S. Public Health Service Guidelines for the 
Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations 
for Postexposure Prophylaxis, 50 MORBIDITY & MORTALITY WKLY. REP. 1 (2001), http:// 
www.cdc.gov/MMWR/preview/mmwrhtml/rr5011a1.htm [http://perma.cc/5726-AWNW])). 
51. For information about TasP as a method of HIV prevention, see HIV Treatment
as Prevention, AVERT, http://www.avert.org/hiv-treatment-as-prevention.htm [http://perma.cc/ 
4VMY-ZGFK] (last updated Jan. 6, 2015). 
52.  Underhill, supra note 28, at 610.
53.  See Clinical Trials, U.S. NAT’L INSTITUTES OF HEALTH, https://www.clinical trials.
gov/ct2/results?term=pre-exposure+prophylaxis+HIV&pg=1 [https://perma.cc/FB5D-ZDR7] 
(last visited Mar. 25, 2015). 
54. The first study, published in 2010, is called the iPrEx (Preexposure Prophylaxis
Initiative) Trial.  This study was a phase III, randomized, double-blind, placebo-controlled trial 
conducted in Brazil, Ecuador, Peru, South Africa, Thailand, and the United States.  See 
Robert M. Grant et al., Preexposure Chemoprophylaxis for HIV Prevention in Men Who 
Have Sex with Men, 363 NEW ENG. J. MED. 2587, 2588 (2010).  The study sample included 
MSM and male-to-female (MTF) transgender adults who self-reported sex with men 
during the six months prior to enrollment.  Id. at 2587, 2592.  Noncontrol group study 
participants received daily oral doses of combination emtricitabine/tenofovir disoproxil 
fumarate (TDF/FTC).  Id. at 2588.  All participants were seen every four weeks for an 
interview, HIV testing, risk-reduction counseling, and dispensing of treatment and 
condoms.  Id.  The iPrEx study yielded an overall forty-four percent reduction in the risk 
of HIV acquisition among the treatment group (ninety-five percent confidence interval 
(CI), 15 to 63, p=0.005).  Id. at 2594.  The results were more favorable for those who 
adhered to the protocols by self-reporting and pill counts.  See id.  When adherence was 
fifty percent, reduction in HIV acquisition was fifty percent, and above ninety percent 
adherence had a seventy-three percent reduction in risk.  Id.  Importantly, for participants 
with some detectible level of Truvada in their systems, there was a ninety-two percent 
reduction of risk.  Id. at 2596–97.  Interestingly, study participants reported a decrease in 
the number of sex partners and an increase in condom usage.  Id. at 2590.  This finding 
suggests that mandatory risk-reduction counseling and regular medical checkups 
associated with the study may have had an impact on risk reduction. 
The significant reduction in risk of infection documented in the iPrEx study was 
confirmed in the second study, the U.S. MSM Safety Trial, published in 2013.  Lisa A. 
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The third studied efficacy in serodiscordant couples.55  The fourth 
completed study pertained to intravenous drug users.56  These clinical 
trials and other studies57 suggest the use of antiretroviral drugs could 
Grohskopf et al., Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil 
Fumarate Among HIV-Uninfected Men Who Have Sex with Men in the United States, 64 
J. ACQUIRED IMMUNE DEFICIENCY SYNDROME 79 (2013).  This study was a phase II 
randomized, double-blind, placebo-controlled study of the clinical safety and behavioral 
effects of TDF/FTC for HIV prevention in 400 MSM participants in Atlanta, Boston, and 
San Francisco.  Id. at 79.  In this study, no HIV infections occurred in study participants 
who were given TDF/FTC.  Id. at 85. 
55. The Partners PrEP Trial was a phase III randomized, double-blind, placebo-
controlled study of daily oral TDF or TDF/FTC combination for the prevention of 
acquisition of HIV by the uninfected partner in 4758 HIV-1 serodiscordant heterosexual 
couples in Kenya and Uganda.  J.M. Baeten et al., Antiretroviral Prophylaxis for HIV 
Prevention in Heterosexual Men and Women, 367 NEW ENG. J. MED. 399, 399 (2012); 
Pamela M. Murnane et al., Efficacy of Preexposure Prophylaxis for HIV-1 Prevention 
Among High-Risk Heterosexuals: Subgroup Analyses from a Randomized Trial, 27 AIDS 
2155, 2156 (2013).  In thirty-eight percent of the couples, the infected partner was male. 
See Baeten, supra, at 401.  Among participants of both sexes combined, efficacy estimates 
for each of the two antiretroviral regimens compared with placebo were sixty-seven 
percent for TDF  (ninety-five percent CI, 44 to 81, p<0.001) and seventy-five percent for 
TDF/FTC (ninety-five percent CI, 55 to 87, p<0.001).  Id. at 404.  Among women, the 
estimated efficacy was seventy-one percent for TDF (p=0.002) and sixty-six percent for 
TDF/FTC (p=0.005).  Id.  Among men, the estimated efficacy was sixty-three percent for 
TDF (p=0.01) and eighty-four percent for TDF/FTC (p=0.005).  Id. 
56. The Bangkok Tenofovir Study was a phase III randomized, double-blind,
placebo-controlled study of the safety and efficacy of daily oral TDF for HIV prevention 
among 2413 injection drug users receiving drug treatment at clinics in Bangkok, Thailand. 
Kachit Choopanya et al., Antiretroviral Prophylaxis for HIV Infection in Injecting Drug 
Users in Bangkok, Thailand (the Bangkok Tenofovir Study): A Randomised, Double-Blind, 
Placebo-Controlled Phase 3 Trial, 381 LANCET 2083, 2083 (2013).  Confidence in this 
study was bolstered by the fact that participants were followed for an average of about five 
years and received directly observed therapy eighty-seven percent of the time.  See Bangkok 
Tenofovir Study: PrEP for HIV Prevention Among People Who Inject Drugs, CENTERS FOR 
DISEASE CONTROL & PREVENTION (June 2013), http://www.cdc.gov/hiv/pdf/prevention_ 
research_prep_BTSfactsheet.pdf.  A post-hoc modified analysis showed the efficacy of 
TDF in plasma was associated with a 73.5% reduction in the risk for HIV acquisition for 
this risk group (ninety-five percent CI, 16.6 to 94.0, p=0.03).  Choopanya, supra, at 2088. 
57.  See, e.g., Paul W. Denton et al., Antiretroviral Pre-Exposure Prophylaxis
Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice, PLOS MED. 84–88 (Jan. 
15, 2008), http://www.plosmedicine.org/article/fetchObject.action?uri=info:doi/10.1371/journal. 
pmed.0050016&representation=PDF [http://perma.cc/U45Q-4RRK]; J. Gerardo García-
Lerma et al., Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent 
Prophylaxis with Emtricitabine and Tenofovir, PLOS MED. 297–98 (Feb. 5, 2008), 
http://www.plosmedicine.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pmed.00
50028&representation=PDF [http://perma.cc/5JWT-9QC6]; Jessica E. Haberer et al., 
Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort Within a 
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“substantially reduce the incidence of HIV transmission in populations at 
high risk of infection.”58  In fact, data from completed trials indicates PrEP 
is up to ninety-two percent effective in reducing the risk of HIV when 
taken daily along with other prevention methods such as condom distribution, 
counseling, and medical oversight.59  According to the CDC, PrEP is “a 
powerful HIV prevention tool” for at-risk groups.60  The at-risk groups for 
whom PrEP prevention has the potential to make a significant impact on 
risk reduction include the following: 
MSM.  The MSM category has the highest HIV incidence rate61—more 
than fifty percent of new HIV infections62—which makes implementation of 
new prevention modalities profoundly important for this group.  For those 
MSM who eschew condoms, PrEP would at least provide some layer of 
Clinical Trial of Serodiscordant Couples in East Africa, PLOS MED. 1, 8–9 (Sept. 10, 
2013), http://www.plosmedicine.org/article/fetchObject.action?uri=info:doi/10.1371/journal. 
pmed.1001511&representation=PDF [http://perma.cc/B24S-MURL]; Shambavi Subbarao et 
al., Chemoprophylaxis with Tenofovir Disoproxil Fumarate Provided Partial Protection 
Against Infection with Simian Human Immunodeficiency Virus in Macaques Given 
Multiple Virus Challenges, 194 J. INFECTIOUS DISEASES 904, 909–10 (2006); Robert M. 
Grant et al., Presentation at the 20th International AIDS Conference: Results of the iPrEx 
Open-Label Extension (iPrEx OLE) in Men and Transgender Women Who Have Sex with 
Men: PrEP Uptake, Sexual Practices, and HIV Incidence (July 22, 2014); Pre-Exposure 
Prophylaxis (PrEP), CENTERS FOR DISEASE CONTROL & PREVENTION, http://www.cdc. 
gov/hiv/prevention/research/prep [http://perma.cc/3TTT-ZXTZ] (last updated Sept. 30, 
2014) [hereinafter CDC PrEP Research Summary]. 
58. Jiang et al., supra note 7, at 2 (citing A. David Paltiel et al., HIV Preexposure
Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, 
and Cost-Effectiveness, 48 CLINICAL INFECTIOUS DISEASES 806, 811–12 (2009); Lynn A. 
Paxton et al., Pre-exposure Prophylaxis for HIV Infection: What if It Works?, 370 LANCET 
89, 89 (2007)).  Researchers have had some difficulty studying PrEP in the African 
continent, particularly with women.  See Jeanne M. Marrazzo et al., Tenofovir-Based 
Preexposure Prophylaxis for HIV Infection Among African Women, 372 NEW ENG. J. MED.
509, 516–17 (2015) (finding during a randomized, placebo-controlled study of African 
Women that no tenofovir-based prophylaxes reduced HIV because the study was hindered 
by low adherence); Donald G. McNeil Jr., A Failed Trial in Africa Raises Questions About 
How To Test H.I.V. Drugs, N.Y. TIMES (Feb. 4, 2015), http://www.nytimes.com/2015/ 
02/05/health/failed-trial-in-africa-raises-questions-about-how-to-test-hiv-drugs.html?_r=0 [http:// 
perma.cc/A7CV-7PGC] (indicating that low adherence may have resulted from a combination 
of financial incentives for participating women, increased access to quality healthcare for 
participating women, and fear of the drug regimens and researchers’ motives). 
59.  CDC GUIDELINES, supra note 1, at 14–15.
60.  CDC PrEP Research Summary, supra note 57.  The CDC maintains an extensive
informational webpage devoted solely to PrEP.  See PrEP, supra note 19. 
61.  Ronald Valdiserri, HIV Among MSM Examined at CROI, AIDS.GOV (Mar. 8,
2013), http://blog.aids.gov/2013/03/hiv-among-msm-examined-at-croi.html [http://perma.cc/ 
3UN9-WLVA]. 
62. 2020 Topics & Objectives: HIV, U.S. DEP’T HEALTH & HUM. SERVICES.,
http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=22 [http:// 
perma.cc/9SGK-UTUD] (last visited Mar. 25, 2015). 
[VOL. 52:  171, 2015] When Condoms Fail 
SAN DIEGO LAW REVIEW 
185 
protection against HIV infection.  For those who do use condoms 
regularly, providing PrEP would furnish another layer of protection to a 
group in which HIV incidence is on the rise.  It would also reduce the fear 
associated with condom failure or misuse during anal intercourse. 
Serodiscordant Couples.  Men and women in serodiscordant relationships 
—relationships in which one partner is HIV-positive63—are also excellent 
candidates for an integrated prevention approach that includes PrEP.  PrEP 
is particularly useful for an HIV-negative female to protect her from 
transmission by her HIV-positive partner during pregnancy attempts, as 
barrier methods would prevent conception.64 
Other High-Risk Populations.  Other appropriate candidates for PrEP 
include sex workers,65 adult entertainment performers,66 intravenous drug 
users,67 and prison populations.68  In this catchall group, the risk of 
63.  See Mixed-Status Couples, AIDS.GOV, http://aids.gov/hiv-aids-basics/staying-
healthy-with-hiv-aids/friends-and-family/mixed-status-couples/index.html#tips [http://perma. 
cc/W6FW-82YY] (last updated Oct. 27, 2014).  Serodiscordant relationships are sometimes 
called serodivergent, serodifferent, or magnetic relationships. 
64.  See Pregnancy & Childbirth, AIDS.GOV, http://www.aids.gov/hiv-aids-basics/
prevention/reduce-your-risk/pregnancy-and-childbirth/index.html [http://perma.cc/HM58-
B3RR] (last updated Jan. 25, 2012); Provider Information Sheet–PrEP During Conception, 
Pregnancy, and Breastfeeding, CENTERS FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/hiv/pdf/PrEP_GL_Clinician_Factsheet_Pregnancy_English.pdf 
[http:// perma.cc/3NWX-4D7Z ] (last visited Mar. 25, 2015). 
65. In a 2014 study of female sex workers in China, among the 405 participants,
85.9% indicated they would accept PrEP it if it was safe and effective.  Li Ye et al., HIV 
Pre-Exposure Prophylaxis Interest Among Female Sex Workers in Guangxi, China, PLOS 
ONE 1, 5 (Jan. 22, 2014), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899205/pdf/pone. 
0086200.pdf [http://perma.cc/FKU3-LAQL].  Of these 348 participants, 54.3% indicated 
they would be willing to participate in a clinical trial.  Id. at 5. 
66.  See generally Tracy Clark-Flory, Move Over, Condoms! Porn Has a New
Debate: HIV Meds, SALON (May 14, 2014, 3:58 PM), http://www.salon.com/2014/05/14/ 
move_over_condoms_porn_has_a_new_debate_truvada [http://perma.cc/H7BX-KX9B] 
(discussing the debate about developing education programs about PrEP in the adult 
entertainment industry). 
67. Injection drug users represented eight percent of all new HIV infections in 2010 
and fifteen percent of those living with HIV in 2011.  HIV in the United States: At a 
Glance, supra note 1 (citing Ctrs. for Disease Control & Prevention, Estimated HIV 
Incidence in the United States, 2007–2010, HIV SURVEILLANCE SUPPLEMENTAL REPORT,
Dec. 2012, at 1, 19; Ctrs. for Disease Control & Prevention, Monitoring Selected National 
HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 
6 Dependent Areas—2012, HIV SURVEILLANCE SUPPLEMENTAL REPORT, Nov. 2014, at 1, 
24–25). 
68. Prison populations are particularly interesting to consider for oral PrEP because,
unlike other risk groups, prisoners’ healthcare can be closely monitored to ensure adherence. 
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transmission immediately upon seroconversion may be greater because 
detection of, and treatment for, HIV before the next risk-taking activity 
may not be possible. 
1. Dodging Friendly Fire on the Road to FDA Approval
The FDA has approved only one medication for oral PrEP called 
Truvada, which is manufactured by Gilead Sciences, Inc. and is available by 
prescription.69  Gilead retains an exclusive patent and no generics are 
currently available in the United States.70  Despite the FDA’s previous 
approval of Truvada for the treatment of HIV/AIDS, the road to 
Truvada’s FDA approval for pre-exposure applications was not a 
particularly smooth one.  Principal opposition to FDA approval of 
Truvada as PrEP came from the largest nonprofit HIV/AIDS healthcare 
provider in the United States, the AHF.71 
Prior to FDA approval, the AHF submitted petitions in response to the 
FDA’s supplemental New Drug Application for Truvada as HIV PrEP.72  
69.  Pre-Exposure Prophylaxis (PrEP), AIDS.GOV, https://www.aids.gov/hiv-aids-
basics/prevention/reduce-your-risk/pre-exposure-prophylaxis/ [https://perma.cc/R38D-
TH69] (last updated May 22, 2014).  One other Gilead tenofovir combination, Viread, as 
well as a number of non-Gilead products, such as Lamivudine (Epivir), Maraviroc 
(Selzentry), Rilpivirine (Edurant), and Raltegravir (Isentress), are being considered for 
PrEP.  See Inge Derdelinckx et al., Criteria for Drugs Used in Pre-Exposure Prophylaxis 
Trials Against HIV Infection, PLOS MED. 2003 (Nov. 7, 2006), http://www.plosmedicine. 
org/article/fetchObject.action?uri=info:doi/10.1371/journal.pmed.0030454&representati
on=PDF [http://perma.cc/MXU4-4Q69]; C. Preston Neff et al., Oral Pre-Exposure 
Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects Against HIV-1 
Vaginal Transmission in a Humanized Mouse Model, PLOS ONE 2, 4 (Dec. 21, 2010), 
http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0015257 
&representation=PDF [http://perma.cc/37LN-8JNB]; Epivir (lamivudine, 3TC), AIDS MEDS, 
http://www.aidsmeds.com/archive/Epivir_1579.shtml (last updated May 4, 2014); Isentress 
(raltegravir), AIDSMEDS, http://www.aidsmeds.com/archive/Isentress_1639.shtml  [http://perma. 
cc/7AA4-R5QY] (last updated Dec. 22, 2011); PrEP Pipeline: Ongoing Research, 
PREPWATCH, http://www.prepwatch.org/prep-research/prep-pipeline-ongoing-research [http:// 
perma.cc/46CS-YMXS] (last visited Mar. 25, 2015). 
70. While a generic alternative to Truvada was developed in India by Lupin
Limited, Lupin appears to have abandoned the effort.  See Lupin No Longer Trying To 
Market Generics of Truvada and Viread, PHARMA LETTER (June 8, 2014), http:// 
www.thepharmaletter.com/article/lupin-no-longer-trying-to-market-generics-of-truvada-and- 
viread [http://perma.cc/2MYB-UGLA]. 
71.  AIDS HEALTHCARE FOUND., http://www.aidshealth.org (last visited Mar. 25,
2015).  According to the AHF’s website, the organization provides medical care and/or 
services in thirty-six countries to more than 404,313 individuals.  Id. 
72.  See Citizen Petition from Tom Myers, Gen. Counsel, AIDS Healthcare Found.,
to the Food & Drug Admin. (Mar. 5, 2012), http://www.regulations.gov/#!document Detail; 
D=FDA-2012-P-0226-0001 [http://perma.cc/L3C2-LLSW] [hereinafter AHF Petition 1]; 
Citizen Petition from Tom Myers, Gen. Counsel, AIDS Healthcare Found., to Food & 
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In its primary petition, the gravamen of the AHF’s opposition was that the 
completed trials failed to demonstrate that the benefits of Truvada as PrEP 
outweighed the risks.73  The AHF’s specific objections to PrEP in its 
primary petition have become the major talking points against PrEP 
subsequent to FDA approval.  As such, in this subpart, I review these 
objections to introduce the enduring criticisms of PrEP treatment. 
In addition to attacking the body of research to argue the efficacy of 
Truvada as PrEP has not been sufficiently established, the AHF argued in 
its primary petition that Truvada’s efficacy must be measured against the 
ninety-five percent efficacy of proper and regular condom usage.74  In a 
response addressing AHF concerns, the FDA rejected this argument, 
finding that actual efficacy of condoms is “much lower[] because many 
individuals do not use them correctly or use them at all.”75 
In addition, the organization made a “real world” argument that study 
conditions did not reflect what regular usage conditions would likely be.76  
It argued that Truvada, if approved, would not be used as indicated.77  The 
FDA also rejected this argument, finding that proper patient education upon 
prescription would alleviate adherence concerns.78  Furthermore, AHF 
argued that adherence would be affected by the significant out-of-pocket 
cost of Truvada,79 but the FDA noted cost is not a factor in approval 
deliberations.80 
Finally, the AHF made three arguments that the negative, long-term 
medical and behavioral effects of Truvada are overwhelming.  First, the 
AHF argued that, even if used as directed, Truvada carries with it a 
“significant—and unacceptable—risk of kidney disease and kidney 
damage.”81  The FDA rejected this argument, noting that the risk of renal 
Drug Admin. (Jun. 8, 2012), http://www.regulations.gov/#!documentDetail; D=FDA-
2012-P-0607-0001 [http://perma.cc/LL6T-BURM] [hereinafter AHF Petition 2]. 
73.  See AHF Petition 1, supra note 72, at 8–9, 26–29.  In its second petition, the
AHF argued that the Antiviral Drugs Advisory Committee’s members had “intellectual 
conflicts of interest.”  AHF Petition 2, supra note 72, at 2–3. 
74. AHF Petition 1, supra note 72, at 16–19.
75. Letter from Janet Woodcock to Tom Myers, supra note 44, at 11 (citing
Pinkerton & Abramson, supra note 37, at 1304, 1306–07). 
76. AHF Petition 1, supra note 72, at 26.
77.  Id.
78. Letter from Janet Woodcock to Tom Myers, supra note 44, at 14.
79. AHF Petition 1, supra note 72, at 10.
80. Letter from Janet Woodcock to Tom Myers, supra note 44, at 22.
81. AHF Petition 1, supra note 72, at 21.
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damage was too infrequent to be significant.82  Second, the AHF argued 
that the use of Truvada would lead to increased drug resistance.83  The 
FDA, while recognizing this is a serious concern, noted that such 
instances during clinical studies occurred in participants who were already 
infected and that proper labeling could mitigate this effect.84  Finally, and 
most memorably, the AHF argued that the use of Truvada as PrEP would 
increase “risk compensation” among MSM, meaning that users “may 
[forgo] highly effective and proven protective measures such as condoms 
in favor of a ‘magic pill’ that is far less effective.”85  The FDA rejected 
this as an empty hypothesis without solid clinical evidence.86 
On July 16, 2012, the FDA approved the safety and efficacy of once-
daily Truvada for HIV prevention in individuals with high risk of sexual 
exposure for use “as part of a comprehensive HIV prevention strategy that 
includes other prevention methods, such as safe sex practices, risk reduction 
counseling, and regular HIV testing.”87  As guidance to physicians, Gilead 
included a list of factors on its package insert to help physicians determine if 
an individual is at high risk of exposure to HIV.  The risks listed include 
the following: 
 has partner(s) known to be HIV-1 infected, or
 engages in sexual activity within a high prevalence area or
social network and one or more of the following:
o inconsistent or no condom use
o diagnosis of sexually transmitted infections
o exchange of sex for commodities (such as money,
food, shelter, or drugs)
o use of illicit drugs or alcohol dependence
o incarceration
82. Letter from Janet Woodcock to Tom Myers, supra note 44, at 15; see also
Choopanya et al., supra note 56, at 2088 (noting that the study “did not find higher rates 
of increased creatinine or renal disease in participants randomly allocated to tenofovir”). 
Since FDA approval, at least one double-blind, placebo-controlled study has confirmed 
that the risk of kidney impairment is small.  See Kenneth K. Mugwanya et al., Changes in 
Glomerular Kidney Function Among HIV-1-Uninfected Men and Women Receiving 
Emtricitabine-Tenofovir Disoproxil Fumerate Preexposure Prophylaxis: A Randomized 
Clinical Trial, 175 JAMA INTERNAL MED. 246, 262–63 (2015). 
83. AHF Petition 1, supra note 72, at 27–28.
84. Letter from Janet Woodcock to Tom Myers, supra note 44, at 21.
85. AHF Petition 1, supra note 72, at 24–26.
86.  See Letter from Janet Woodcock to Tom Myers, supra note 44, at 10–11.
87. Press Release, Food & Drug Admin., FDA Approves First Drug for Reducing
the Risk of Sexually Acquired HIV Infection (Jul. 16, 2012), http://www.fda.gov/ 
NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. 
[VOL. 52:  171, 2015] When Condoms Fail 
SAN DIEGO LAW REVIEW 
189 
o partner(s) of unknown HIV-1 status with any of the
factors listed above.88
The FDA strengthened the package’s boxed warning advising healthcare 
professionals that, among other things, individuals must be confirmed 
HIV negative and retested every three months during use.89  The FDA also 
required Gilead to establish a program to educate, train, and assist 
prescribers.90 
2. Final CDC Guidance
On May 14, 2014, the U.S. Public Health Service, an agency within the 
U.S. Department of Health and Human Services (HHS) that serves as a 
parent agency to the CDC, issued an authoritative set of clinical practice 
guidelines for PrEP.91  The CDC guidelines are intended for an audience 
of primary care physicians, clinicians providing substance abuse treatment, 
infectious disease specialists, and health policymakers.92  The CDC’s PrEP 
report recommends oral PrEP for four groups: (1) MSM “at substantial 
risk of HIV acquisition,” (2) heterosexual men and women at substantial 
risk, (3) serodiscordant couples, particularly when pregnancy is involved, 
and (4) intravenous drug users.93 
Based on a review of published literature, including the major clinical 
trials referenced herein,94 the CDC recommended to primary care 
practitioners that “clinicians evaluate their male and female patients who 
are sexually active or who are injecting illicit drugs and consider offering 
PrEP as one prevention option to those whose sexual or injection behaviors 
88.  Gilead Sciences, Inc., Truvada: Package Insert and Label Information,
DRUGINSERTS (last revised Dec. 23, 2013), https://druginserts.com/lib/rx/meds/truvada-5/ 
(emphases added). 
89.  Important Safety Information, GILEAD, http://www.truvadapreprems.com/truva
daprep-safety-profile [http://perma.cc/TLB5-AV79] (last visited Mar. 25, 2015). 
90.  See Truvada for a Pre-Exposure Prophylaxis (PrEP) Indication: REMS
Information, GILEAD, http://www.truvadapreprems.com/online-training [http://perma.cc/ 
384T-AH3E] (last visited Mar. 25, 2015). 
91.  CDC GUIDELINES, supra note 1.  These final guidelines incorporated a number
of interim reports on the subject.  Id. at 16–18, 21. 
92.  Id. at 13.
93.  Id. at 9.
94.  See supra notes 54–56 and accompanying text.
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and epidemiologic context place them at substantial risk of acquiring HIV 
infection.”95 
The CDC report is groundbreaking from a public health standpoint, as 
the CDC guidance encouraging primary care practitioners to consider 
PrEP for at-risk patients could increase the utilization of PrEP in the 
mainstream.96  Recognizing the opportunity to implement oral PrEP on a 
broader scale, 164 HIV/AIDS health and advocacy organizations 
including AIDS Action Committee, amfAR, Gay Men’s Health Crisis, 
and Lambda Legal endorsed the move shortly after the CDC released its 
guidelines.97 
III. CHALLENGES TO PREP IMPLEMENTATION
Since the CDC issued its guidance, interest in oral PrEP has been high.98  
However, as of this writing, multiple data sets indicate the number of 
Truvada prescriptions for PrEP is less than 10,000, though exact 
utilization nationwide is difficult to assess.99  With such a slow uptake, 
95.  CDC GUIDELINES, supra note 1, at 12.
96.  See infra notes 135–136, 217 and accompanying text.
97. Press Release, supra note 24, at 1–2.
98.  See, e.g., Stephanie E. Cohen et al., High Interest in Preexposure Prophylaxis
Among Men Who Have Sex with Men at Risk of HIV Infection: Baseline Data from the 
U.S. PrEP Demonstration Project, 68 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES 
(forthcoming Apr. 2015) (concluding that “interest in PrEP is high among a diverse 
population of MSM at risk for HIV infection when offered in sexually transmitted disease 
and community health clinics”); Albert Liu et al., Early Experiences Implementing Pre-
Exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco, PLOS MED. 1, 1 (Mar. 
4, 2014), http://www.plosmedicine.org/article/fetchObject.action?uri=info:doi/10.1371/ 
journal.pmed.1001613&representation=PDF [http://perma.cc/3NP5-BAB4] (noting that “interest 
in PrEP is high in San Francisco”). 
99. A Gilead analysis presented in late 2014 of prescription data from fifty-five
percent of pharmacies in the United States identified and studied 3253 people that have 
been prescribed the drug since January of 2012.  Charlene Flash et al., Presentation at the 
2014 International Congress of Drug Therapy in HIV Infection: Two Years of Truvada for 
Pre-Exposure Prophylaxis Utilization in the United States (Nov. 2–6, 2014), 
http://www.natap.org/2014/GLASGOW/GLASGOW_10.htm [http://perma.cc/S678-VPM9]. 
The 2014 Gilead utilization numbers do not include those receiving PrEP through 
Medicaid.  Email communication with Jim Pickett, Dir. of Prevention Advocacy & Gay 
Men’s Health, AIDS Found. of Chicago, (Jan. 4, 2015).  Another study presented in 2014 
indicated that only 2317 prescriptions for Truvada as PrEP were filled in the United States 
between 2012 and 2013.  Robert M. Grant et al., Presentation at the 2014 World AIDS 
Conference in Melbourne: Pre-Exposure Prophylaxis (PrEP) Initiative: Open Label 
Extension (July 22, 2014), http://pag.aids2014.org/PAGMaterial/PPT/4961_3462/final. 
pptx [http://perma.cc/A56S-JEFJ].  At the local level, in December of 2014, Kaiser indicated 
that approximately 500 of its members were taking PrEP in San Francisco.  See Liz 
Highleyman, No New HIV Infections Seen Among Kaiser PrEP Users, AIDSMAP (Dec. 15, 
2014), http://www.aidsmap.com/No-new-HIV-infections-seen-among-Kaiser-PrEP-users/page/ 
2929303 [http://perma.cc/KLF7-GKBY].  Of those taking PrEP, the majority of the users 
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some PrEP advocates have sounded the alarm.100  It is particularly irksome 
to some HIV prevention advocates that the AHF continues to take a wait 
and see position on PrEP, only recommending its use in “very limited” 
scenarios, such as in the context of sex workers and serodiscordant 
couples.101  Yet this is only a small segment of the high-risk population 
that stands to benefit from the layer of protection that PrEP provides. 
Despite the AHF’s objections to PrEP and the growing frustration about 
its underutilization, efforts to educate high-risk communities,102 physicians,103 
and lawmakers104 have burgeoned.  In fact, there has been significant 
movement recently at the state and local levels.  For example, New York 
Governor Andrew Cuomo recently became the first high-ranking 
lawmaker to endorse oral PrEP.105  With Cuomo’s support, the New York 
City Department of Health and Mental Hygiene developed a PrEP 
education campaign that provides numerous resources for both patients 
and providers.106  According to Cuomo’s administration, the justification 
for supporting PrEP implementation efforts is the need to provide a basic 
between 2012 and 2013 were women.  Mark Mascolini, Presentation at the 53rd Interscience 
Conference on Antimicrobial Agents and Chemotherapy: Almost Half of Early US PrEP 
Are Women, Often in Southern States (Sept. 10–13, 2013), http://www.natap.org/2013/ 
ICAAC/ICAAC_04.htm [http://perma.cc/J5GJ-PALS]. 
 100.  See 31 Days of PrEP, ADVOCATE, http://www.advocate.com/31-days-prep 
[http://perma.cc/K3JS-Q8U2] (last visited Mar. 25, 2015) (featuring in-depth articles from 
PrEP advocates focusing on “why the HIV-prevention drug has not been more widely 
accepted”). 
 101.  See Principles on Prevention of AIDS Healthcare Foundation, AIDS HEALTHCARE 
FOUND., http://www.aidshealth.org/wp-content/uploads/2014/06/AHF-Principles-of-Prevention. 
pdf [http://perma.cc/X5HW-3BTB] (last visited Mar. 25, 2015) [hereinafter Principles on 
Prevention]. 
 102.  See, e.g., Is PrEP or PEP for You?, GAY MEN’S HEALTH CRISIS, http:// 
www.gmhc.org/prep [http://perma.cc/9FAT-BHR6] (last visited Mar. 25, 2015). 
 103.  See, e.g., Howard Grossman, I’m an HIV Physician. And I’m Starting PrEP, 
BODY PRO (July 11, 2014), http://www.thebodypro.com/content/74724/im-an-hiv-
physician-and-im-starting-prep.html?ap=1100 [http://perma.cc/6KJE-BZE5]. 
 104.  See, e.g., Josh Barro, With Cuomo’s Plan To Fight AIDS, New Approach Gains 
a Prominent Backer, N.Y. TIMES, July 4, 2014, at A15, http://nyti.ms/1kiDgmC 
[http://perma.cc/SMU7-VT88]. 
 105.  Id. 
 106.  See New Ways To Prevent HIV, N.Y. CITY DEP’T HEALTH & MENTAL HYGIENE, 
http://www.nyc.gov/html/doh/html/living/prep-pep.shtml [http://perma.cc/WJR4-YPAH] (last 
visited Mar. 25, 2015). 
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layer of protection from HIV.107  One official in San Francisco, who 
publically disclosed his own experience taking PrEP, proposed that the 
city provide cost-free access to PrEP to anyone who requests the 
medication.108  Additionally, Washington State109 and Illinois110 now operate 
drug assistance programs for Truvada as PrEP.  The support of officials 
in New York, Washington State, Illinois, and San Francisco is exactly the 
type of public relations exposure that PrEP proponents need to reach at-
risk individuals who are currently unaware of PrEP, who would continue 
to engage in risk-taking activities with or without it, and who would 
maintain a high risk of contracting HIV unless introduced to new, 
attractive, and effective prevention modalities such as PrEP.111 
However, there are two fundamental challenges to full implementation 
that advocates will need to address.  These challenges are acceptability 
and accessibility.  PrEP must be acceptable to the high-risk communities 
who are the targeted users.  PrEP must also be acceptable as a legitimate 
prevention method to the providers who would furnish the medication and 
 107.  Barro, supra note 104 (according to a member of Governor Cuomo’s administration: 
“Some people use condoms, some people don’t . . . .  You can’t offer condoms to people 
who don’t want them”). 
 108.  See Chris Roberts, SF Supervisor To Call for Free HIV Prevention Medication, S.F.
EXAMINER (Sept. 16, 2014), http://www.sfexaminer.com/sanfrancisco/sf-supervisor-to-
call-for-free-hiv-prevention-medication/Content?oid=2899573 [http://perma.cc/UF9V-HMRF]. 
 109.  See Pre-Exposure Prophylaxis Drug Assistance Program (PrEP DAP), WASH.
STATE DEP’T OF HEALTH, http://www.doh.wa.gov/YouandYourFamily/Illness andDisease/ 
HIVAIDS/HIVCareClientServices/PrEPDAP [http://perma.cc/EA42-T6K2] (last visited 
Mar. 25, 2015). 
 110.  See Pre-Exposure Prophylaxis (PrEP), ILL. DEP’T PUB. HEALTH, http://dph. 
illinois.gov/topics-services/diseases-and-conditions/hiv-aids/pre-exposure-prophylaxis-prep 
[http://perma.cc/775C-YNLZ] (last visited Mar. 25, 2015). 
 111.  From the perspective of a twenty-one year old African-American taking PrEP 
as part of a clinical study: “I don’t know what I would do without that pill.  I would 
probably have HIV right now. . . .  I probably could be dead right now. . . .  The pill was 
a blessing to me.”  Kimberly Koester et al., Presentation at the 20th International AIDS 
Conference: Sex on PrEP: Qualitative Findings from the iPrEx Open Label Extension 
(OLE) in the US (July 22, 2014), http://pag.aids2014.org/PAGMaterial/PPT/1151_2462/ 
sex%20on%20prep%20final.pptx [http://perma.cc/X8PC-LUTT].  See HIV incidence 
among young, African-American MSM in Atlanta is comparable to the general population in 
high prevalence areas in Sub-Saharan Africa.  Holly Korschun, U.S. Black Gay, Bisexual 
Men Have Much Higher HIV Infection Rates, EMORY NEWS CENTER (July 24, 2012), 
http://bit.ly/1v9lmaN [http://perma.cc/W82F-G33B] (discussing an Emory School of 
Public Health study called HPTN 061); The Atlanta Principles, ACT UP N.Y., http:// 
actupny.com/actions/files/The_Atlanta_Principles.pdf [http://perma.cc/L6Q7-3ABF] (twelve 
percent of young black gay men in Atlanta are infected with HIV every year) (last visited 
Mar. 25, 2015).  Of all the high-risk populations, the infection risk among young African-
American MSM is particularly troubling.  In the Emory School of Public Health’s HPTN 061 
study, researchers found that in the cohort studied, men sexually active at age eighteen run 
a startling sixty percent chance of contracting HIV by age thirty.  Id. 
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monitor treatment.  To ensure accessibility, PrEP must be coverable by 
health plans, affordable to consumers across the socioeconomic spectrum, and 
procurable with little complication or delay.  Those seeking fuller 
implementation will need to address both acceptability and accessibility 
to successfully fold PrEP into established HIV prevention methods across 
the United States and to ensure its sustainability. 
A.  Acceptability 
It takes courage, honesty, and self-awareness to examine one’s sexual 
behavior and make a determination about one’s actual risk of HIV 
infection.  Those at risk of HIV infection who are honest about their 
current and future risk face stigmatization.  It also takes courage and 
honesty to discuss one’s risk openly with a medical provider.112  In one 
activist’s frank words, there is a perception that people who actively 
consider their risk of HIV infection “must be very, very slutty.”113  Just 
like oral contraception was associated with female debauchery during the 
rollout of “the pill” in the 1960s, PrEP has been associated with reckless 
sexual behavior and irresponsibility.114  For example, in a New York Times 
op-ed piece, AIDS activist Larry Kramer suggested that PrEP would 
contribute to the complacent attitudes of “the lucky uninfected [who] neglect 
or reject condom use.”115  However, there is little evidence that PrEP 
increases risk-taking activity.  In fact, recent research suggests the contrary.116  
Unfounded hypotheses that PrEP increases risk-taking activity contribute to 
public attitudes about the illegitimacy of PrEP, which has harmed 
implementation efforts. 
To make PrEP acceptable, proponents must change social, individual, 
and systemic biases against those who use it.  Stigma, and the discrimination 
 112.  See HIV Stigma, UNLOCKING HIV, http://unlockinghiv.com/?page_id=402 
[http://perma.cc/3V2N-NRQT] (last visited Mar. 25, 2015) (quoting UN Secretary-
General Ban Ki-moon as saying that “too many people are afraid to see a doctor to 
determine whether they have the disease, or to seek treatment if so”). 
 113.  Stern, supra note 8 and accompanying text. 
 114.  See Duran, supra note 21. 
115.  Larry Kramer, Opinion, We Don’t Know the Full Effects of Truvada Yet, N.Y. 
TIMES, http://www.nytimes.com/roomfordebate/2014/06/17/is-prep-a-good-way-to-fight-
hiv-infections/we-dont-know-the-full-effects-of-truvada-yet [http://perma.cc/DP7L-QWE8] (last 
updated June 18, 2014, 12:07 PM). 
 116.  Koester et al., supra note 111 (noting that “PrEP use, in most cases, did not lead 
to increased condomless sex”). 
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that accompanies it, can occur at the self-imposed, individual, and 
institutional levels.117  Self-imposed stigma occurs when a person expects 
the application of a certain stereotype and “a priori acts as if discrimination 
has already been imposed.”118  In the context of healthcare, self-imposed 
stigma typically occurs before an individual decides whether to actively seek 
a practitioner’s advice.  By way of example, many women in the 1960s 
feared that pondering risk of unwanted pregnancy or even considering 
family planning effectively meant that they were insubordinate and unallied 
with their husbands’ desires.119  Individual stigma, on the other hand, 
occurs when one person imposes a negative judgment on another; this stigma 
is more easily noticeable.120  Again, recalling birth control implementation 
in the 1960s, debate over oral contraception during its early implementation 
pit men against women and women against themselves.  Use of the pill 
implied that users were currently engaging in, and planning to engage in, 
immoral behavior.121  Finally, institutional bias, sometimes known as 
structural or systemic bias, is more indirect and often appears to be normal 
behavior.122  Such biases occur when institutional practices in the aggregate 
disadvantage certain groups.123  This could also be seen during early 
implementation of oral contraception, as the prevalence of male physicians 
and their traditional assumptions may have had an indirect discriminatory 
effect on women who were already uncomfortable speaking to a man 
about contraception.124  As a result of these trifold stigmatic forces, 
 117.  Anish P. Mahajan et al., Stigma in the HIV/AIDS Epidemic: A Review of the 
Literature and Recommendations for the Way Forward, 22 AIDS S67, S70 (2008) (citing 
Bruce G. Link & Jo C. Phelan, Conceptualizing Stigma, 27 ANN. REV. SOC. 363, 365 
(2001)). 
 118.  Id. (citing Link & Phelan, supra note 117, at 373–75; Elizabeth C. Pinel, Stigma 
Consciousness: The Psychological Legacy of Social Stereotypes, 76 J. PERSONALITY & SOC. 
PSYCHOL. 114, 126 (1999); Ronald O. Valdiserri, HIV/AIDS Stigma: An Impediment to Public 
Health, 92 AM. J. PUB. HEALTH 341, 341 (2002)). 
 119.  See People & Events: The Pill and the Sexual Revolution, PBS, http:// 
www.pbs.org/wgbh/amex/pill/peopleevents/e_revolution.html [http://perma.cc/EKW5-GJKB] 
(last visited Mar. 25, 2015). 
 120.  See Link & Phelan, supra note 117, at 372. 
 121.  See LARA V. MARKS, SEXUAL CHEMISTRY: A HISTORY OF THE CONTRACEPTIVE
PILL 198 (2001). 
 122.  See CHRISTA TOBLER, INDIRECT DISCRIMINATION: A CASE STUDY INTO THE
DEVELOPMENT OF THE LEGAL CONCEPT OF INDIRECT DISCRIMINATION UNDER EC LAW 62 
(2005) (citing Nicola Lacey, Legislation Against Sex Discrimination: Questions from a 
Feminist Perspective, 14 J.L. SOC’Y 411, 417–18 (1987)). 
 123.  See Link & Phelan, supra note 117, at 373–74; Mahajan, supra note 117, at 
S70. 
 124.  See generally Marks, supra note 121, at 116 (noting that “many doctors in the 
early 1960s were opposed to prescribing the pill”). 
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procuring the pill in the early years of its introduction took, in the words 
of one scholar, “a great deal of nerve.”125 
The similarities between the effect of stigma on women seeking birth 
control in the 1960s and the effect of stigma on at-risk individuals seeking 
oral PrEP are uncanny.  In the context of pharmacological HIV prevention 
modalities, like in the context of birth control, stigma is also present at the 
self-imposed, individual, and institutional levels.  Some at-risk individuals 
fail to even consider taking PrEP, as they believe that actively considering 
HIV prevention beyond condom usage means that one is promiscuous and 
reckless.  At the conscious level, those seeking PrEP are often concerned 
about how they will be perceived by their doctors, by their community, 
and by their sexual partners.126  Individual stigma is manifested, like in 
the birth control context, in the acrimonious debate both within the general 
population and within the high-risk communities poised to benefit from 
PrEP prevention.127 
Negative provider attitudes about PrEP at the individual level also 
contribute to the stigmatization of those who seek it.  Indeed, there is 
anecdotal evidence that, for an individual who has already decided to seek 
out PrEP, securing insurance coverage is not the biggest barrier to 
obtaining a prescription.  Rather, it is convincing the medical provider to 
prescribe PrEP.128  The attitudes of medical providers at the individual 
level negatively impact the utilization of PrEP.129  Some medical providers 
are too unfamiliar with PrEP to prescribe it, and some view prescription 
of ARVs “as the purview of HIV specialists.”130  Even HIV specialist 
 125.  Id. at 205. 
 126.  See Stern, supra note 8. 
 127.  Id.; Duran, supra note 21 and accompanying text. 
 128.  See Truvada Track–Monitoring Insurance and Medicaid Coverage of Truvada 
for PrEP, MY PREP EXPERIENCE, http://myprepexperience.blogspot.com/p/truvada-track. html 
[http://perma.cc/WQP9-5LLX] (last visited Mar. 25, 2015) [hereinafter MY PREP
EXPERIENCE]. 
 129.  See, e.g., David Tuller, supra note 50 (noting that “[s]ome men have reported 
receiving negative reactions from their health care providers when they brought it up”). 
 130.  Reilly O’Neal, Getting Comfortable with PrEP: A Provider’s Perspective, 
BETA BLOG (Mar. 26, 2014), http://betablog.org/getting-providers-comfortable-with-prep/ 
[http://perma.cc/Z6SA-L5D6] (interviewing HIV specialist Dr. Joel Gallant, MD, MPH, 
who relayed the results of a recent think tank meeting with providers); see generally S.F. 
AIDS FOUND., GAY MEN’S SEXUAL HEALTH THINK TANK MEETING (2013),
http://www.sfaf.org/hiv-info/hot-topics/from-the-experts/gay-mens-sexual-health-think-
tank-report.pdf [http://perma.cc/TF4T-SNDX] (providing overview of discussions among 
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willingness to prescribe Truvada for PrEP is on the low side according to 
a number of studies.  In a June 2013 study, for example, 1175 physician 
members of the Infectious Disease Society of America’s Emerging 
Infections Network (EIN) were given a ten-part questionnaire to evaluate 
current PrEP attitudes and practices.131  Although seventy-five percent of 
responding specialists indicated they were in support of using the 
prophylactic drug regimen, only nine percent reported they had prescribed 
it to patients.132  The EIN study identified that: 
Common reasons for unwillingness to prescribe PrEP included fears about 
adherence and resistance, concerns about cost and reimbursement, reluctance to 
use a potentially toxic medication in healthy people and reservations about 
efficacy.  Some physicians raised concerns about risk compensation and there were 
occasional “moral” objections, one physician stating: “Medicine should not attempt 
to reverse bad behaviors artificially.”133 
In addition, a 2013 study of 189 HIV physicians found that although the 
majority of HIV specialists knew about the existence of PrEP, only one 
out of five of those specialists reported actually prescribing it.134  Other 
studies support these findings.135  The final CDC guidelines represent a 
significant step forward in changing providers’ attitudes about PrEP.  In 
fact, the New York Times recently predicted the CDC report could result 
in a fifty-fold increase in Truvada prescriptions for PrEP—from fewer 
more than twenty national leaders and experts about how to best improve provider-client 
communications around HIV prevention strategies). 
 131.  Maile Y. Karris et al., Are We Prepped for Preexposure Prophylaxis (PrEP)? 
Provider Opinions on the Real-World Use of PrEP in the United States and Canada, 58 
CLINICAL INFECTIOUS DISEASES 704, 705 (2014). 
 132.  Id.; Barro, supra note 104. 
 133.  Michael Carter, Widespread Support for HIV PrEP Among Infectious Disease 
Doctors in the US and Canada, AIDSMAP (Dec. 17, 2013), http://www.aidsmap.com/ 
Widespread-support-for-HIV-PrEP-among-infectious-disease-doctors-in-the-US-and-Canada/ 
page/2810626 [http://perma.cc/MTU8-W7D7]. 
 134.  See David Tellalian et al., Pre-Exposure Prophylaxis (PrEP) for HIV Infection: 
Results of a Survey of HIV Healthcare Providers Evaluating Their Knowledge, Attitudes, 
and Prescribing Practices, 27 AIDS PATIENT CARE & STDS 553, 554 (2013); Mark 
Mascolini, Only 1 in 5 US HIV Doctors Surveyed Uses PrEP, Despite High Awareness, 
BLACK AIDS INST., http://www.blackaids.org/news-2013/1899-only-1-in-5-us-hiv-doctors- 
surveyed-uses-prep-despite-high-awareness [http://perma.cc/7F67-VQEY] (last visited Mar. 
25, 2015). 
 135.  See, e.g., Jaclyn M. White et al., Evolution of Massachusetts Physician 
Attitudes, Knowledge, and Experience Regarding the Use of Antiretrovirals for HIV 
Prevention, 26 AIDS PATIENT CARE & STDS 395, 397 (2012), http://www.ncbi.nlm. 
nih.gov/pmc/articles/PMC3432573/pdf/apc.2012.0030.pdf [http://perma.cc/C77Y-5SAL].  In 
fact, as of 2013, the majority of prescriptions have been from nonphysician prescribers, 
such as nurse practitioners and physician assistants.  See Mascolini, supra note 99. 
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than 10,000 to 500,000.136  Even supposing these numbers are exaggerated, 
this prediction illustrates the strong effect the CDC report will have on 
providers who have been hesitant to prescribe PrEP, ambivalent about 
doing so, simply unaware of the prevention method, or believe it is 
unavailable to primary care practitioners.  At a minimum, the CDC guidelines 
may be a vehicle for dialogue about high-risk behavior between providers 
and high-risk patients, as providers often have difficulty beginning these 
dialogues.137 
PrEP bias at the institutional level is the most difficult to identify. 
Institutional bias against those who seek or use PrEP prevention exists by 
virtue of a healthcare system that is only beginning to support the coding, 
billing, and medical supervision that PrEP treatment requires.138  For 
example, the current medical coding system, which insurers require 
physicians to use to track conditions, treatments, services, and medications, 
makes it difficult for physicians who have never prescribed PrEP to code 
the treatment.  There are sixty billing codes related to HIV prevention that 
might apply to a PrEP-related clinical profile, but there are no billing 
codes that specifically pertain to PrEP treatment.139  Widespread provider 
confusion over proper coding can further complicate access, frustrate 
patients, and may lead to underutilization and future coverage denials.140 
 136.  Donald G. McNeil Jr., Advocating Pill, U.S. Signals Shift To Prevent Aids, N.Y. 
TIMES, May 15, 2014, at A1, http://www.nytimes.com/2014/05/15/health/advocating- pill-us-
signals-shift-to-prevent-aids.html?r=0 [http://perma.cc/S9C7-PRU8]. 
 137.  See Jonathan Mermin, From the CDC: HIV Prevention in the Doctor’s Office, 
MEDPAGE TODAY (Nov. 30, 2009), http://www.medpagetoday.com/Columns/And-Now-
a-Word/17193 [http://perma.cc/RPU5-4VSK] (noting that “many doctors avoid talking 
about risk behaviors because they assume it makes patients uncomfortable”); see generally 
Ronald M. Epstein et al., Awkward Moments in Patient-Physician Communication About 
HIV Risk, 128 ANNALS INTERNAL MED. 435 (1998), http://goo.gl/a8ZZKb [http://perma. 
cc/RX2L-6P45] (discussing the troubles physicians have communicating with high-risk 
patients because of inadequate professional, educational, and cultural training to fully 
assess the risks associated with HIV/AIDS). 
 138.  S.F. AIDS FOUND., supra note 130, at 4 (noting that current models of HIV care 
are “not well suited for PrEP delivery”). 
 139.  S.F. AIDS FOUND., PREP FACTS 10 (2014), http://prepfacts.org/assets/PrEP_ 
Facts_16-pager_brochure_mech_FINAL.pdf (noting that “[c]urrently, there are no official 
ICD-9 or ICD-10 codes” specifically for PrEP).  The most relevant billing code for PrEP 
is “high risk sexual behavior” (V69.2 and Z72.5, ICD-9 and ICD-10, respectively).  See 
id. at 11–13.  However, physicians may be using other codes. 
 140.  Some organizations have already begun educating physicians about billing code 
accuracy pertaining to PrEP.  See Pre-Exposure Prophylaxis (PrEP) for HIV Prevention, 
CENTERS FOR DISEASE CONTROL & PREVENTION (May 2014), http://www.cdc.gov/hiv/ 
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Additionally, the USPSTF, which directly affects the prescription habits 
of providers and coverage determinations of insurance issuers, has not yet 
taken into special consideration the differential healthcare needs of 
marginalized, high-HIV-incidence communities.141  In the aggregate, 
these and other institutional factors negatively impact those seeking PrEP 
and delegitimize their unique preventive healthcare needs. 
Just as the self-imposed, individual, and institutional stigmatization of 
women in the context of birth control has proved a difficult challenge to 
overcome and continues today, so too will the multidimensional stigmas 
associated with those who take PrEP.142  Community education efforts 
have been, and will continue to be, a key part of the advocacy response,143 
and the ACA provides grant opportunities that may be appropriate for 
establishing practitioner, clinician, and community health worker training 
vis-à-vis oral PrEP.144  Additionally, in their effort to eliminate the various 
pdf/PrEP_fact_sheet_final.pdf [http://perma.cc/24AD-7WZ7].  More information is needed 
about how insurers identify oral PrEP applications and whether coverage determinations 
vary based upon the billing codes ascribed. 
 141.  See infra note 289 and accompanying text. 
 142.  See, e.g., Maggie Fazeli Fard, Sandra Fluke, Georgetown Student Called a 
“Slut” by Rush Limbaugh, Speaks Out, WASH. POST (Mar. 2, 2012, 11:06 AM), 
http://wapo.st/xlpoRt [http://perma.cc/DQS3-JPFU]. 
143.  Education efforts in the media can incorporate research indicating PrEP usage 
does not result in decreased condom usage. See, e.g., Julia L. Marcus et al., No Evidence 
of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure 
Prophylaxis, PLOS ONE 2, 5, 7 (Dec. 18, 2013), http://www.plosone.org/article/fetchObject. 
action?uri=info:doi/10.1371/journal.pone.0081997&representation=PDF [http://perma.cc/ 
4FAH-AH4V]; see also Koester et al., supra note 111 (noting that “PrEP use, in most 
cases, did not lead to increased condomless sex”). Educational efforts directed toward 
PrEP users can include information about dosage, contraindications, and corequisites to 
treatment such as routine follow-up visits and HIV testing and counseling on safer-sex 
practices.  At the provider level, educational efforts can focus on training practitioners on 
how to introduce discussions about HIV risk, accurately explain the risks and benefits 
associated with PrEP, and properly code the treatment. See Ronald M. Epstein et al., 
Talking about AIDS, 13 AIDS PATIENT CARE & STDS 545, 546 (1999). Additional research 
will also be a key aspect of changing provider attitudes about PrEP. See Emily A. Arnold 
et al., A Qualitative Study of Provider Thoughts on Implementing Pre-Exposure 
Prophylaxis (PrEP) in Clinical Settings To Prevent HIV Infection, PLOS ONE 1, 6–7 (July 
11, 2012), http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal. 
pone.0040603&representation=PDF [http://perma.cc/Z9P4-42JD]; see generally Josh 
Barro, Is Truvada, the Pill To Prevent H.I.V., 99 Percent Effective? Don’t Be So Sure, 
N.Y. TIMES (July 16, 2014), http://www.nytimes.com/2014/07/17/upshot/is-truvada-the-
pill-to-prevent-hiv-99-percent-effective-dont-be-so-sure.html?_r=3 [http://perma.cc/U8VG-6UD8]. 
 144.  The ACA created the Prevention and Public Health Fund, which was 
established “to provide for expanded and sustained national investment in prevention and 
public health programs to improve health and help restrain the rate of growth in private 
and public sector health care costs.”  42 U.S.C. § 300u-11 (2012); Corey S. Davis & Sarah 
Somers, National Health Care Reform and the Public’s Health, 39 J.L. MED. & ETHICS 
65, 66 (Supp. 2011).  Under the ACA, the Fund may disburse up to fifteen billion dollars 
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stigmas attached to oral PrEP on a national scale, PrEP proponents should 
seek legal and public policy solutions.  The stigmatization of PrEP users 
and its concomitant underutilization may be an appropriate justification 
for seeking mandatory low cost or cost-free access to PrEP through 
federal and state laws and regulations.145 
B.  Accessibility 
In addition to acceptability challenges, challenges related to the 
accessibility of oral PrEP are a core concern to those seeking fuller 
implementation.146  There is anecdotal evidence that major commercial 
insurers and Medicaid programs are currently covering Truvada as PrEP, 
which is facilitating more affordable access.147  United Healthcare, for 
example, the largest commercial insurer in the United States, is covering 
PrEP with a prior authorization.148  However, there is little information 
about policy coverage of PrEP across the industry, and there are few 
resources to compare coverage.149 
Because there are currently no federal or state laws or regulations 
requiring insurers to cover oral PrEP, whether insurers will continue to 
ride or buck the trend of covering the prevention modality is a great 
unknown for PrEP proponents.  Will some insurers subject PrEP treatment 
requests to more rigorous utilization review?  What is the cost of PrEP 
treatment?  Are there provisions in benefit plans that insurers could invoke 
to deny coverage for PrEP in the future?  Is PrEP medically necessary? 
Answering these questions will require careful analysis. 
to fund education programs for physicians and community prevention programs.  See 
Davis & Somers, supra, at 66; Secretary Sebelius Announces $250 Million To Strengthen 
the Primary Health Care Workforce, AM. ASS’N COLLEGES NURSING, http://www.aacn. 
nche.edu/government-affairs/archives/secretary-sebelius-announces-250-million-to-strengthen- 
the-primary-health-care-workforce [http://perma.cc/WW6A-SDMV] (last visited Mar. 25, 
2015). 
 145.  See infra notes 323–27 and accompanying text. 
 146.  See Underhill, supra note 28, at 610. 
 147.  See MY PREP EXPERIENCE, supra note 128. 
 148.  See id.  Authorization is issued for one month if the beneficiary meets the requirements.  
See UnitedHealthcare Pharmacy: Clinical Pharmacy Programs, UNITEDHEALTHCARE, https:// 
www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStatic 
Files/ProviderStaticFilesPdf/Tools%20and%20Resources/Pharmacy%20Resources/Notifi 
cation_Truvada.pdf [https://perma.cc/7L8Q-3PSE] (last visited Mar. 25, 2015). 
 149.  See generally MY PREP EXPERIENCE, supra note 128 (indicating that “[w]e have 
not heard of any insurance company or any Medicaid program outright denying coverage 
of Truvada as PrEP”). 
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1. Cost of Oral PrEP Prevention
The entryway to understanding the accessibility challenges that PrEP 
proponents face is to itemize the various costs associated with PrEP 
prevention.150  Few studies have addressed the total cost of providing oral 
PrEP treatment.151 
There are multiple dimensions to oral PrEP treatment in addition to the 
cost of medication.  As part of the “comprehensive HIV prevention 
strategy” recommended by the FDA, prior to receiving a prescription for 
Truvada as PrEP, the practitioner must conduct a number of preliminary 
tests, which include screenings for HIV and other sexually transmitted 
infections, tests for hepatitis B, and analyses of kidney function.152  Once 
treatment begins, cost inputs associated with PrEP prevention include but 
may not be limited to (1) lab fees in connection with quarterly HIV tests 
and periodic kidney function analyses, (2) professional fees and services, 
such as counseling and follow-up visits, and (3) the cost of the medication 
itself.153 
In calculating the various insurer outputs to providers, Medicare fee 
schedules, which list Medicare fees used to pay healthcare providers, are 
an excellent place to begin because they are “the platform around which 
insurers and physicians often negotiate.”154  According to one 2013 study 
that analyzed the total “cost components” of PrEP using this payment 
schedule, the aggregate cost associated with PrEP prevention is nearly 
$18,000 per year in the United States.155  This includes the price of 
 150.  See Michael Horberg & Brian Raymond, Financial Policy Issues for HIV Pre-
Exposure Prophylaxis: Cost and Access to Insurance, 44 AM. J. PREVENTIVE MED. S125,
S125 (2013), http://www.ajpmonline.org/article/S0749-3797(12)00696-4/pdf [http://perma.cc/ 
TP2W-GFRJ?type=live]. 
 151.  Id. (citing two studies: Kamal Desai et al., Modeling the Impact of HIV 
Chemoprophylaxis Strategies Among Men Who Have Sex with Men in the United States: 
HIV Infections Prevented and Cost-effectiveness, 22 AIDS 1829 (2008), and Paltiel et al., 
supra note 58). 
 152.  See PROJECT INFORM, IS TAKING PREP THE RIGHT CHOICE FOR YOU? 9 (2014), 
http://www.projectinform.org/pdf/prep_msm.pdf [http://perma.cc/H742-RQ8D]. 
 153.  See Horberg & Raymond, supra note 150, at S126. 
 154.  Jeffrey Clemens, How Medicare Shapes the US Health Sector, ECON. ACTION 
(May 6, 2014), http://economics.ucsd.edu/economicsinaction/issue-10/headline.php 
[http://perma.cc/AEM5-P5QJ]; see Lenard I. Lesser et al., Comparison Between US 
Preventive Services Task Force Recommendations and Medicare Coverage, 9 ANNALS
FAM. MED. 44, 48 (2011), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022045/ 
pdf/0090044.pdf [http://perma.cc/A4YU-T34V]; Medicare-Covered Preventive Services, 
AM. C. PHYSICIANS, http://www.acponline.org/advocacy/where_we_stand/assets/iii8-
medicare-covered-preventive-services.pdf [http://perma.cc/8LFV-T4ZH] (last visited Mar. 25, 
2015). 
 155.  See Horberg & Raymond, supra note 150, at S126 (citing Truvada, BODY (Mar. 
2012), www.thebody.com/content/art1331.html [http://perma.cc/9L8Y-4WZ9]; PANEL ON
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Truvada, which the study estimated at $1425 per month on average.156  
Using this estimated price for the purpose of illustration, the yearly cost 
of the medication alone is approximately $17,125.08.157  Additionally, the 
associated costs of FDA-required and CDC-recommended laboratory 
work are estimated at $373.50 to $504.51 per year, which includes an 
initial HIV screening.158  Medical services, including the costs of 
determining eligibility for PrEP, the initial prescription, periodic patient 
evaluations, and risk-reduction counseling, are estimated at $309.86 per 
year.159  There may also be additional costs in connection with adverse 
events, such as drug interactions and side effects, should they occur.160  
Thus, the cost of covering PrEP involves more than considering the price 
of the drug.  PrEP is more than a drug, after all, it is a treatement regimen. 
Even if actuarial calculations favor coverage and an insurer grants 
benefits for PrEP treatment, PrEP may still be inaccessible to at-risk 
patients due to maximum out-of-pocket deductibles, high monthly copays, 
and coinsurance.161  Private and public copay assistance programs have 
ANTIRETROVIRAL GUIDELINES FOR ADOLESCENTS & ADULTS, U.S. DEP’T OF HEALTH &
HUMAN SERVS., GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-1-INFECTED 
ADULTS AND ADOLESCENTS K-23 (2014), http://aidsinfo.nih.gov/contentfiles/lvguidelines/ 
adultandadolescentgl.pdf [http://perma.cc/U4WP-3PEA]. 
 156.  Id. at S125.  For a table containing the various cost inputs, what those inputs 
include, and the annual cost of each input, see id. at S126. 
 157.  Id.  For a comparable estimate, see Michael Hornberg, Presentation: PrEP: 
Access and Cost from Private Sector Payor (n.d.), http://www.iapac.org/tasp_prep/presentations/ 
TPSlon12_Panel7_Horberg.pdf [http://perma.cc/TS7G-BR7H] (estimating the cost of 
Truvada at $16,697.40 per year (citing 2012 Clinical Diagnostic Laboratory Fee Schedule, 
CENTER FOR MEDICARE & MEDICAID (2012), http://www.cms.gov/apps/ama/license.asp?file=/ 
ClinicalLabFeeSched/downloads/12CLAB.ZIP [http://perma.cc/3TSB-T7VF] [hereinafter 
Fee Schedules])). 
158.  Horberg & Raymond, supra note 150, at S126 (citing Fee Schedules, supra note 
157). 
 159.  Id. 
 160.  Id. at S127. 
 161.  In fact, some insurers have structured their prescription drug benefit plans to 
place HIV medications, including Truvada, on specialty drug tiers with high cost sharing, 
which, according to the AIDS Institute and the National Health Law Program, requires 
patients to shoulder between forty and fifty percent of the cost of the medication.  See 
Melinda Beck, Cigna Agrees To Restructure HIV Drug Benefits, WALL ST. J., http://www. 
wsj.com/articles/cigna-agrees-to-restructure-hiv-drug-benefits-1415404871 [http://perma.cc/ 
4WNR-DPP3] (last updated Nov. 7, 2014, 7:11 PM); AIDS Found. of Chi., Presentation: 
Your Six-Month Health Reform Check-Up: Assessing Initial Implementation of Health 
Reform for People with HIV 16 (June 24, 2014), http://www.hivhealthreform.org/wp-
content/uploads/2014/06/6_Month_ACA_Checkup_slides.pdf [http://perma.cc/5N7M-SLBA] 
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helped make PrEP more affordable.  For example, Gilead offers copay 
assistance on a sliding scale to those with qualifying incomes,162 which 
has reduced many copays to the $0 to $60 range.163  On the public side, 
two states operate their own copay assistance programs.164  Successful 
state programs have the potential to be replicated in other states, which 
could help make PrEP more affordable on a broader scale. 
However, there are concerns with conditioning access to HIV prevention 
on a drug manufacturer’s assistance program and even on state programs. 
First, requiring patients to secure copay assistance from either the 
manufacturer or a state creates an additional obstacle to procuring the 
medication, which may dissuade some patients from following through. 
Second, assistance programs may not be sustainable over time.  On 
the drug manufacturer side, assistance programs could be phased out or 
qualifying income requirements could change at any time.  On the public 
side, state assistance programs facilitated by health officials can be 
affected by administration changes and budget cuts.  As such, assistance 
programs should be only one part of the solution to securing affordable 
access to PrEP treatment in the future.165 
(noting that “[s]ome plans are placing all HIV and HCV medications on tiers that require 
50% coinsurance”); Letter from HIV Health Care Access Working Group, to Kathleen 
Sebelius, Sec’y, U.S. Dep’t of Health & Human Servs. 2 (Dec. 2, 2013), https://www. 
aahivm.org/Upload_Module/upload/Advocacy/letter%20to%20HHS%20on%20QHPs%
20and%20anti%20retro%20coverage%20concerns(12%202%2013%20HHS%20Concern
s%20Letter%20WAD%20Final).pdf [https://perma.cc/F9UL-R2GN] (listing six examples of 
“troubling plan cost-sharing designs” that render ARVs unaffordable). 
 162.  See Paying for Truvada, GILEAD, http://www.truvada.com/truvada-patient-
assistance [http://perma.cc/Q8AS-6HKU] (last visited Mar. 25, 2015). 
 163.  See PrEP Facts: Rethinking HIV Prevention & Sex, FACEBOOK, https://www. 
facebook.com/groups/PrEPFacts [https://perma.cc/A738-8TJL] (last visited Aug. 9, 2014) 
(of over fifty individuals responding to an inquiry about how much their copay for Truvada 
as PrEP was, the majority cited amounts in the $0 to $60 range). 
 164.  Washington State’s assistance program is open to at-risk Washington residents 
with specific risk factors regardless of need.  The program will pay the copay for Truvada 
for those with insurance and will cover the entire cost of Truvada for those without 
insurance.  WASH. STATE DEP’T OF HEALTH, HIV PREVENTION PROGRAM FOR PEOPLE THAT
ARE AT RISK OF HIV INFECTION  2 (2014), http://www.doh.wa.gov/Portals/1/Documents/ 
Pubs/150-055-PrEPDAPBrochure.pdf [http://perma.cc/HL5Z-T5MJ].  Illinois’ assistance 
program will cover the entire cost of Truvada for those without insurance who meet 
specific income criteria.  See Pre-Exposure Prophylaxis (PrEP), ILL. DEP’T PUB. HEALTH, 
http://dph.illinois.gov/topics-services/diseases-and-conditions/hiv-aids/pre-exposure-prophylaxis 
-prep [http://perma.cc/T6Z5-47R8] (last visited Mar. 25, 2015). 
 165.  See John Anoysius Cogan Jr., The Affordable Care Act’s Preventive Services 
Mandate: Breaking Down the Barriers to Nationwide Access to Preventive Services, 39 
J.L. MED. & ETHICS 355, 358–59 (2011). 
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2. Prior Authorization and Medical Necessity
In addition to the cost of PrEP prevention, another accessibility challenge 
PrEP proponents face is eliminating or streamlining the insurance barriers 
patients may face subsequent to their provider consultation and before 
securing the medication.  These barriers, which may include prior 
authorization, paperwork, wait time, and potentially denials based on 
medical necessity exclusions, typically occur during utilization review, a 
mechanism that insurers use to evaluate benefit usage. 
Utilization review is used, sometimes under different names, in all health 
insurance programs, including government programs such as Medicare 
and Medicaid.166  The utilization review process functions to ensure 
healthcare benefits are rendered only for services that are covered by the 
benefit plan, suitable for the treatment, and medically necessary under the 
circumstances.167  Types of utilization review are prospective review, 
often called “prior authorization,”168 concurrent review,169 and retrospective 
review.170  While classic utilization review of coverage decisions 
happens retrospectively after the insurer issues the benefit, much of 
utilization review today occurs prospectively before benefits have been 
granted.171  This is especially the case with expensive or risky medications, 
treatments, services, and equipment.  In the context of PrEP prevention, 
which comes at a significant cost to the insurer, the most common form 
of utilization review that patients experience is the prior authorization.172 
 166.  Michael A. Dowell, Avoiding HMO Liability for Utilization Review, 23 U. TOL. 
L. REV. 117, 117 (1991). 
 167.  See id.; Health Utilization Management, URAC, https://www.urac.org/accreditation- 
and-measurement/accreditation-programs/all-programs/health-utilization-management [https:// 
perma.cc/R9JQ-E6KV] (last visited Mar. 25, 2015). 
 168.  Answers to Frequently Asked Questions About Utilization Review (UR) for 
Claims Administrators, CAL. DEP’T. INDUS. RELATIONS (Mar. 2014), http://www.dir.ca. 
gov/dwc/UtilizationReview/UR_FAQ.htm [http://perma.cc/73FE-GPG5]. 
 169.  See J. Scott Andresen, Is Utilization Review the Practice of Medicine?: 
Implications for Managed Care Administrators, 19 J. LEGAL MED. 431, 434 (1998). 
 170.  Benjamin Saunier, The Devil Is in the Details: Managed Care and the Unforeseen 
Costs of Utilization Review as a Cost Containment Mechanism, 27 ISSUES L. & MED. 21, 
33 (2011) (citing Allison Faber Walsh, The Legal Attack on Cost Containment Mechanisms: 
The Expansion of Liability for Physicians and Managed Care Organizations, 31 J. MARSHALL
L. REV. 207, 217 (1997)). 
 171.  See INST. OF MED., CONTROLLING COSTS AND CHANGING PATIENT CARE? THE
ROLE OF UTILIZATION MANAGEMENT 3 (Bradford H. Gray & Marilyn J. Field eds., 1989). 
 172.  See MY PREP EXPERIENCE, supra note 128. 
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Prior authorization is an insurer requirement that medical providers 
must, except for emergencies, obtain permission before services will be 
rendered or prescriptions will be filled.173  Most insurers maintain a list of 
drugs requiring prior authorization.174  Prior authorization policies for 
Truvada used as PrEP are by no means uniform across private or public 
healthcare programs.  Some insurers require it,175 while others are covering it 
without prior authorization.176  Prior authorizations for Truvada as PrEP 
can result in “additional delays and treatment interruptions.”177  Additionally, 
prior authorizations can place an additional burden on providers “because 
they require the doctor, rather than other staff to request them monthly.”178 
Prior authorizations also require additional communication between 
providers and patients179 and thorough documentation of medical 
appropriateness180—why the patient would benefit from the service181—
 173.  See 5 DOUGLAS DANNER ET AL., MEDICAL MALPRACTICE: CHECKLISTS AND
DISCOVERY § 36:9 (rev. ed. 2014).  For an example of an insurer’s prior authorization 
policy, see UNITEDHEALTHCARE, OXFORD PROVIDER REFERENCE MANUAL: COMMERCIAL 
PLANS 10–12 (2013), https://www.oxhp.com/secure/materials/providers/prm/PRM.pdf 
[https://perma.cc/7DNZ-8WNV]; Mark A. Hall & Gerard F. Anderson, Health Insurers’ 
Assessment of Medical Necessity, 140 U. PA. L. REV. 1637, 1654 (1992) (citing INST. OF
MED., supra note 171, at 3, 17–18, 66). 
 174.  See, e.g., Drugs Requiring Prior Authorization, HEALTH NET, https://www. 
healthnet.com/static/general/unprotected/pdfs/ca/pharmacy/drugs_requiring_pa.pdf [https:// 
perma.cc/RP7M-BM43] (last updated Feb. 1, 2015). 
 175.  See MY PREP EXPERIENCE, supra note 128; see, e.g., NYS Medicaid Pharmacy 
Prior Authorization Programs, MAGELLAN, https://newyork.fhsc.com/providers/CDRP_ 
truvada.asp [https://perma.cc/GM9T-QPWN] (last visited Mar. 25, 2015). 
 176. See, e.g., Medication Request Forms (MRF) and Clinical Coverage Criteria, 
HARV. PILGRIM HEALTH CARE, https://www.harvardpilgrim.org/portal/page?_pageid 
=253,234249&_dad=portal&_schema=PORTAL [https://perma.cc/VL5X-76SG] (last 
visited Mar. 25, 2015); Preferred Drug List, EMPIRE BLUE (July 2014), http://www. 
empireblue.com/national/noapplication/f0/s0/t0/pw_e181120.pdf [http://perma.cc/6D4B-
ZDCS]; Drug List, CIGNA, https://my.cigna.com/teamsite/cgi-bin/customer_care/member/drug_ 
list/DrugList.cgi?search_by=name&rxPlanType=&rxPlanDesign=&LeanIndicator=&ref
erer=&Pid= [https://perma.cc/E3WU-NN3F] (last visited Mar. 25, 2015); Rx Prior 
Authorization, ANTHEM, http://www.anthem.com/pharmacyinformation/priorauth.html 
[http://perma.cc/C5F7-JS7M] (last visited Mar. 25, 2015). 
 177.  Barriers to HIV Medication Access, N.Y. ST. DEP’T HEALTH AIDS INST., 
https://www.health.ny.gov/diseases/aids/ending_the_epidemic/docs/key_resources/care_
committee/medication_access/barriers_to_medication.pdf [https://perma.cc/EFA8-WE3X] 
(last visited Mar. 25, 2015). 
 178.  Id. 
 179.  See id. 
 180.  See Saunier, supra note 170, at 34 (citing Walsh, supra note 170, at 217). 
 181.  See, e.g., Medical Necessity Guidelines, TUFTS HEALTH PLAN, http://www. 
uftshealthplan.com/providers/provider.php?sec=pharmacy&content=pharmacy_medical_
necessity_guidelines [http://perma.cc/SR6A-6MKX] (last visited Mar. 25, 2015) (“If a 
physician feels that a patient would benefit from a service, device or equipment requiring 
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by the provider.  Finally, incorrect ARV coding on prior authorization 
forms resulting from provider confusion may lead to benefit denials.182  
Therefore, it will be important to streamline the prior authorization 
process for PrEP in the future. 
In addition to the administrative prior authorization barrier to PrEP 
access, another potential barrier to access in the future could be interpretation 
of policy terms such as medical necessity exclusions.183  An insurer may 
be less inclined to cover an additional layer of HIV prevention if 
administrators determine that condoms offer a medically effective and 
less expensive alternative or that PrEP is merely a prevention of comfort 
or convenience to the patient.  It is also possible, particularly after the U.S. 
Supreme Court’s Burwell v. Hobby Lobby ruling, that religiously affiliated 
insurers may rely on policy language to exclude PrEP prevention, a 
treatment some religious organizations may regard as facilitating or even 
encouraging promiscuous and unsafe sexual practices.184  As such, a 
discussion of benefit policy language that limits coverage, especially medical 
necessity clauses, is important to understanding some of the accessibility 
challenges PrEP proponents may face in the future. 
The modern definition of medical necessity is a “multidimensional” one 
containing a number of different elements.185  Across the industry, there 
is “widespread consensus” that medical necessity definitions should have 
specific elements, though these elements may be articulated in different 
ways depending on the policy.186  Consider the following pre-ACA Blue 
Cross Blue Shield definition of medical necessity: 
prior authorization, the physician must submit the appropriate clinical documentation for 
review.”). 
 182.  See Barriers to HIV Medication Access, supra note 177, at 2. 
 183.  See Saunier, supra note 170, at 33.  Another policy term that may be of some 
concern in the future is the experimental treatment exclusion.  Currently, it is unlikely that 
an oral PrEP request would be subject to an experimental treatment exclusion, as the 
FDA’s approval of Truvada as PrEP, the CDC’s final guidance, and a thorough literature 
review would likely render the prevention nonexperimental.  However, in the future, 
should physicians experiment with other ARVs as PrEP or with off-label dosage regimens 
of Truvada, experimental treatment exclusions may indeed come into play. 
 184.  See Burwell v. Hobby Lobby Stores, Inc., 134 S. Ct. 2751, 2779 (2014). 
 185.  SARA ROSENBAUM ET AL., U.S. DEP’T OF HEALTH & HUMAN SERVS., MEDICAL
NECESSITY IN PRIVATE HEALTH PLANS: IMPLICATION FOR BEHAVIORAL HEALTH CARE 34 
(2003), http://goo.gl/6hFwd6 [http://perma.cc/LHQ8-W5WA]. 
 186.  Id. at 33. 
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[The plan will use] the following criteria for establishing the medical necessity of 
a service: appropriate for symptoms, diagnosis, and treatment of a condition, 
illness, or injury; provided for diagnosis, direct care, or treatment; in accordance 
with the standards of good medical practice; not primarily for the convenience of 
the member or member’s provider; the most appropriate supply or level of service 
that can be safely provided to the member.187 
The first element of most modern medical necessity definitions is 
“contractual scope” language, which limits benefits to certain purposes, 
such as the treatment of a disease.188  In the definition above, this may be 
found in the inclusion of “treatment of a condition, illness, or injury . . . 
provided for diagnosis, direct care, or treatment.”189  The second element 
of most definitions is “professional standard” language, which limits benefits 
to those that are standard practice in the industry.190  In the definition 
above, this element may be found in the language, “in accordance with 
the standards of good medical practice.”191  The third element is safety 
and appropriateness language, which limits coverage to treatments that 
are safe, effective, and appropriate for the particular patient.192  Also in 
the definition above, this element may be found in the language, “the most 
appropriate supply or level of service that can be safely provided to the 
member.”193  The last element contained in most modern medical necessity 
definitions is convenience language, which limits benefits to treatments 
that are not made primarily for convenience or “that emanate[] from social 
or environmental factors.”194  This element may be seen in the above 
language, “not primarily for the convenience of the member or member’s 
provider.”195 
In the next subpart, I consider each of these common elements of 
medical necessity clauses in relation to oral PrEP. 
i. Contractual Scope
The first element of a common medical necessity definition is language 
purporting to limit the scope of the benefit plan.  Prior to implementation 
 187.  Id. at 50 tbl.2 (reciting Highmark Blue Cross Blue Shield’s 2000 medical necessity 
definition). 
 188.  Id. at 33. 
 189.  See id. at 50 tbl.2. 
 190.  Id. at 33. 
 191.  See id. at 50 tbl.2. 
 192.  See id. at 33. 
 193.  See id. at 50 tbl.2. 
 194.  See id. at 33; see also Medical Necessity Definitions, CIGNA, http://www. 
cigna.com/healthcare-professionals/resources-for-health-care-professionals/clinical-pay 
ment-and-reimbursement-policies/medical-necessity-definitions [http://perma.cc/TC35-
T26S] (last visited Mar. 25, 2015) (providing a similar definition of “medical necessity”). 
 195.  See Rosenbaum et al., supra note 185, at 50 tbl.2. 
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of the ACA on January 1, 2014, most commercial insurers included in 
their medical necessity definitions a threshold requirement that services 
would be covered only if they treat an illness, injury, condition, or 
disease.196  For example, the excerpt of the pre-2014 Blue Cross Blue 
Shield plan above contains the following language: “[A] service [must be] 
appropriate for symptoms, diagnosis, and treatment of a condition, illness, 
or injury.”197  According to definitions such as this one, treatment in 
connection with preventing a condition, illness, or injury, however, would 
 196.  See Underhill, supra note 28, at 641–42 (citing STEVEN PLITT ET AL., 10A
COUCH ON INSURANCE 3D §§ 144.32, 144.34 (2005)); see, e.g., AETNA, 2013–2014
STUDENT HEALTH INSURANCE PLAN, UNIVERSITY OF SOUTHERN CALIFORNIA 90 (2012) 
[hereinafter AETNA USC PLAN], https://engemannshc.usc.edu/files/2012/12/Aetna-Plan-
Document.pdf [https://perma.cc/2P4A-NR4C] (defining “medically necessary” as what is 
necessary and appropriate “for the diagnosis or treatment of a sickness[] or injury”); 
KAISER PERMANENTE, A HEALTH MAINTENANCE ORGANIZATION (HIGH, STANDARD AND
BASIC OPTIONS) 72 (2014), healthplans.kaiserpermanente.org/federalemployees/wp-content/ 
uploads/sites/2/2013/09/2014_KP__CAN_73-003_FEHB_brochure_131002_1_.pdf [http:// 
perma.cc/3V7V-HQR8] (“[W]e will not cover [the service or drug] unless it is medically 
necessary to prevent, diagnose, or treat your illness, disease, injury, or condition.”).  For 
the minority of plans that have nonperil medical necessity definitions, PrEP may satisfy 
this threshold language.  For example, the Blue Cross Blue Shield’s medical necessity 
definition states that “[m]edical necessity shall mean . . . care . . . provide[d] to a patient 
for the purpose of preventing, evaluating, diagnosing, or treating an illness, injury, disease, 
or its symptoms.”  BLUE CROSS & BLUE SHIELD ASS’N, BLUE CROSS AND BLUE SHIELD
SERVICE BENEFIT PLAN 144 (2014), http://www.opm.gov/healthcare-insurance/tribal-
employers/plan-information/plan-codes/2014/brochures/71-005i.pdf [http://perma.cc/EN2B-
JQV4]; see also AETNA, AETNA HEALTHFUND CDHP/AETNA VALUE PLAN 143 (2014) 
[hereinafter AETNA HEALTHFUND CDHP], http://www.aetnafeds.com/pdf/2014/2014CDHP 
ValueBrochure.pdf [http://perma.cc/JWR4-SB89] (“‘Medically necessary’ means . . . for 
the purpose of preventing, evaluating, diagnosing or treating an illness, injury or disease 
or its symptoms . . . .”); CIGNA, COLUMBIA UNIVERSITY HR BENEFITS SUMMARY PLAN 
DESCRIPTION 10 (2013), http://hr.columbia.edu/sites/default/files/document-files/2014/12/05/ 
cigna_pos_100_officers.pdf [http://perma.cc/TVT2-UVXA] (defining medically necessary 
services as those “provided for the purpose of preventing, diagnosing or treating an acute 
Sickness, Injury, mental disorder”); UHA HEALTH INSURANCE, MEDICAL NECESSITY
DECISION POLICY 1 (2013), https://www.uhahealth.com/uploads/forms/form_mis_medical- 
necessity-decision.pdf [https://perma.cc/P45D-775U ] (defining medical necessity as “for 
the purpose of preventing, diagnosing or treating an illness, injury, disease or its symptoms”).  
Truvada as PrEP would appear to satisfy this threshold language because Truvada is 
furnished for the purpose of preventing a disease—HIV.  However, even if PrEP satisfies 
one portion of the medical necessity definition contained in a nonperil contract, it may not 
satisfy other requirements under the plan’s medical necessary definition, such as the 
requirement that services must “not [be] primarily for the convenience of the patient.”  
CIGNA, supra, at 90. 
 197.  Rosenbaum et al., supra note 185, at 50 tbl.2 (reciting Highmark Blue Cross 
Blue Shield’s 2000 medical necessity definition). 
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have been susceptible to benefit denials, as insurers could have argued 
that when treatment occurs in association with an illness that has not yet 
occurred or when the patient is asymptomatic, the beneficiary cannot be 
said to be suffering from any condition.198  PrEP is pre-exposure treatment 
rendered prior to HIV infection.  Accordingly, PrEP may have fallen 
outside the scope of basic policy language in multi-peril contracts pre-
2013/2014.199 
However, after implementation of the ACA in 2014,200 all health plans 
in the individual and small group market, with the exception of grandfathered 
plans in force on or before March 23, 2010,201 must cover a range of 
categories of treatments, including preventive care, under the EHBP.202  
In addition, under the PSP, insurers must also cover specific preventive 
treatments recommended by the USPSTF.203  Because individual and small 
group market insurers are required to offer preventive care pursuant to 
EHBP and PSP, insurers have begun modifying their medical necessity 
definitions to expressly include the term prevention alongside the terms 
treatment and diagnosis in their contractual scope language.204  For example, 
Blue Cross Blue Shield includes the following contractual scope language 
in one of its 2014 policies: “[W]e will not cover [a service or drug] unless 
we determine it is medically necessary to prevent, diagnose, or treat your 
illness, disease, injury, or condition.”205  All but one 2013-2014 commercial 
plan reviewed for this Article contain similar language.206  As a result of this 
change, oral PrEP could fall within the contractual scope of these post-
ACA medical necessity definitions.  After all, oral PrEP is prescribed to 
prevent the disease of HIV, which would likely satisfy the representative 
language above. 
 198.  See Underhill, supra note 28, at 641–42. 
 199.  See id. 
 200.  See infra text accompanying note 291. 
 201.  See infra Part IV.B. 
202.  See infra Part IV.B. 
 203.  See infra Part IV.A. 
 204.  See infra note 206 and accompanying text. 
 205.  BLUE CROSS & BLUE SHIELD ASS’N, supra note 196, at 125 (emphasis added). 
 206.  See AETNA HEALTHFUND CDHP, supra note 196, at 14 (“[F]or the purpose of 
preventing, evaluating, diagnosing, or treating an illness, injury or disease or its 
symptoms . . . .”); CIGNA, supra note 196, at 10 (“[P]rovided for the purpose of preventing, 
diagnosing or treating an acute Sickness, Injury, mental disorder . . . .”); UHA, supra note 
196, at 1 (“[P]rovide to the patient for the purpose of preventing, diagnosing or treating an 
illness, injury, disease or its symptoms . . . .”).  But see AETNA USC PLAN, supra note 196, 
at 90 (defining medical necessity as what is necessary and appropriate “for the diagnosis 
or treatment of a sickness[] or injury”). 
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On the other hand, some insurers, including Blue Cross Blue Shield, 
have begun specifically itemizing their covered preventive benefits.207  If 
PrEP is not a listed preventive treatment, an insurer could determine that 
PrEP falls outside the scope of the term prevention within its medical 
necessity definition, particularly if the insurer defines prevention as 
limited to the specific itemized preventions on the insurer’s covered list. 
In addition, certain plans, such as grandfathered plans, may not include 
prevention in their contractual scope language.208  In these circumstances, 
an insured belonging to a high-risk group could argue that oral PrEP still 
satisfies the contractual scope element, as his or her increased susceptibility 
to HIV by virtue of high-risk conduct—or merely belonging to a high-
prevalence group—is itself a condition for the purpose of satisfying 
threshold medical necessity language.209  In other words, the insured could 
argue during the appeals process that simply belonging to a high-risk 
group, such as the African-American MSM group in which the risk of 
infection is quite high, makes him or her more susceptible to contracting 
HIV.210  Nonetheless, to argue that potential exposure to HIV by virtue of 
 207.  E.g., GEISINGER HEALTH PLAN, GEISINGER CHOICE PPO WITH NO REFERRAL
REQUIRED AND PREVENTIVE SERVICES: SUMMARY OF BENEFITS (2011), https://www.thehealth 
plan.com/documents/smallbiz/PPOSOB.pdf; HORIZON BLUE CROSS BLUE SHIELD OF N.J., 
HEALTH CARE REFORM: USING PREVENTIVE CARE FOR A HEALTHIER LIFE, (2013), 
http://www.horizonblue.com/sites/default/files/pdf/Preventive_Care_Guide_4-9-13.pdf [http:// 
perma.cc/NNP2-38ZD]; see also CIGNA, A GUIDE TO CIGNA’S PREVENTIVE HEALTH
COVERAGE FOR HEALTH CARE PROFESSIONALS 4–11 (2013), http://www.cigna.com/assets/ 
docs/health-care-professionals/807467h-Preventive-Health-Cov-Guide.pdf [http://perma.cc/527M- 
TXH3] (listing Cigna’s covered preventive benefits). 
 208.  See infra note 314 and accompanying text. 
 209.  There is at least one case that supports the idea that susceptibility to a disease 
can itself be considered an illness, particularly when there is a predisposition that makes 
the illness more likely and the susceptibility is a diagnosable condition.  See Katskee v. 
Blue Cross/Blue Shield of Nebraska, 515 N.W.2d 645, 651 (Neb. 1994).  For example, in 
Katskee, the Nebraska Supreme Court found that susceptibility to cancer was a condition, 
illness, or disease under policy terms.  Id. at 653.  However, the susceptibility in that case 
involved a genetic predisposition to breast cancer, and the susceptibility was itself a 
diagnosed condition—breast-ovarian carcinoma syndrome.  Id. at 651. 
210.  It would also be possible for the insured to argue that the condition is “contact 
with and (suspected) exposure to [HIV],” which is a diagnosable condition.  See 2015 ICD-
10-CM Diagnosis Code Z20.6, ICD10DATA, http://www.icd10data.com/ICD10CM/Codes/ 
Z00-Z99/Z20-Z28/Z20-/Z20.6 [http://perma.cc/4TGN-SKK8] (last visited Mar. 25, 
2015).  However, a diagnosis of exposure to HIV likely indicates a PEP application and 
not a PrEP application.  A PEP application, though related, is quite distinct.  See Body 
Fluid Exposure Procedure, UMASS MEMORIAL 2 (2009), http://www.umassmed.edu/Page 
Files/47836/Body%20Fluid%20Exposure%20Procedure%205%2014%2008.pdf 
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belonging to a high-risk group is a disease, illness, or condition may have 
dangerous consequences.211  This would risk perpetuating negative 
attitudes toward members of high-risk groups as it essentially associates 
membership in a high-risk group with pathology, abnormality, or 
sickness.212  It could be especially damaging to LGBT individuals, whose 
sexual orientation has been characterized by the medical community as 
pathological in the past.213 
There continues to be a great deal of variation in contractual scope 
language across benefit plans.  For PrEP seekers with benefit plans that 
include prevention within the contractual scope language and explicitly 
include PrEP as a covered prevention, it is likely that oral PrEP meets the 
first element of the medical necessity analysis.  On the other hand, for 
PrEP seekers with benefit plans that exclude prevention in their medical 
necessity definitions or that do not explicitly cover PrEP as a covered 
benefit, it is possible that benefits could be excluded based on the contractual 
scope element, as there are no federal or state laws or regulations requiring 
PrEP coverage. 
ii. Standard Practice in the Industry
A standard practice element in multi-element medical necessity 
definitions relates primarily to a practitioner’s judgment in comparison to 
practices across the industry.214  Some benefit plans may refer to internal 
guidelines as to what standard practice means for that particular insurer.215 
 The question with regard to oral PrEP here is whether PrEP treatment 
comports with standard industry practice given that the modality is 
relatively new and underutilized.216  The FDA approval of Truvada for 
PrEP applications in high-risk groups should be instructive to utilization 
review administrators.  However, the fact that PrEP is FDA approved does 
not necessarily mean that prescription of Truvada as PrEP is standard HIV 
prevention for members of high-risk groups.  On the other hand, the final 
CDC guidelines recommending that primary care practitioners prescribe 
[http://perma.cc/AQG6-5ZG7] (instructing practitioners to use the exposure to HIV/AIDS 
code for PEP).  But see Stacey L. Murphy, AIDS Education & Training Centers National 
Center for HIV Care in Minority Communities Presentation: HIV/AIDS Care: The 
Diagnosis Code Series 2, at 9 (n.d.), www.healthhiv.org/modules/info/files/files_5152a91 
c11dde.pdf [http://perma.cc/ LMA7-ZK6S] (indicating that an “exposure to HIV/AIDS” 
code may be appropriate for PrEP applications). 
 211.  See Underhill, supra note 28, at 650. 
 212.  See id. 
 213.  See id. 
 214.  See Rosenbaum et al., supra note 185, at 12. 
 215.  See id. 
 216.  Id. at 1. 
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PrEP for HIV prevention in high-risk groups have begun to move standard 
practice in the industry toward PrEP coverage.217  If PrEP utilization 
continues to increase and the introduction of PrEP becomes regular 
protocol in provider-patient discussions about high-risk conduct, it is 
likely that an insured would meet this element of a medical necessity 
definition. 
iii. Safety and Appropriateness
Safety and appropriateness language concerns whether the treatment 
“will be delivered in a manner that the insurer considers to be safe and 
effective.”218  In determining the safety of a prescribed treatment, plan 
administrators consider whether scientific evidence supports the safety of 
the treatment for the patient.219  Some benefit plans specifically define the 
term scientific evidence to include such evidence as “controlled clinical 
trials that either directly or indirectly demonstrate the effect of the treatment 
on health outcomes,” observational studies, peer-reviewed studies published 
in medical journals, major biomedical compendia, and research conducted 
in connection with federal institutes or health-related agencies.220 
Although there has been some debate surrounding the actual effectiveness 
of Truvada as PrEP, potential side effects, and adherence, completed 
clinical trials of PrEP have indicated at least some appreciable effect of 
Truvada as PrEP on health outcomes.221  In addition, both the FDA and 
the CDC have confirmed the safety and efficacy of Truvada.222  Although 
 217.  See generally Public Reporting of Hospital-Acquired Infection Rates: 
Empowering Consumers, Saving Lives: Hearing Before the Subcomm. on Oversight and 
Investigations of the H. Comm. on Energy and Commerce, 109th Cong. 41 (2006) (“CDC 
guidelines serve as the standard of care in U.S. hospitals and guide the clinical practices 
of physicians, nurses and other providers.” (statement of Denise Cardo, Chief, Div. of 
Healthcare Quality Promotion, Centers for Disease Control and Preventention)); see also 
supra Part II.A; notes 147–49 and accompanying text. 
 218.  Rosenbaum, supra note 185, at 12–13. 
 219.  Id. at 8 (citing Sara Singer et al., Decreasing Variation in Medical Necessity 
Decision Making: Final Report to the California HealthCare Foundation (Aug. 1999) 
(unpublished manuscript) (on file with Center for Health Policy, Stanford University), http:// 
www.chcf.org/publications/1999/08/decreasing-variation-in-medical-necessity-decision-
making [http://perma.cc/KT59-822U]). 
 220.  See UHA PLAN, supra note 196, at 5. 
 221.  See supra notes 53–61 and accompanying text.  The 2015-published trial of 
African women, which indicated no reduction in HIV acquisition, was abandoned due to 
low adherence.  See Marrazzo et al., supra note 58. 
 222.  See supra Parts II.A–B.2. 
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both agencies recognized some concerns about long-term side effects, 
subsequent research continues to indicate side effects are minimal.  However, 
research is not complete, and given the continued debate over the safety 
and appropriateness of PrEP, there is still a risk that some insurers could 
deny coverage based on safety and appropriateness language.223 
Utilization review administrators should be encouraged to grant more 
deference to the physician’s determination of whether PrEP is safe and 
appropriate for the particular patient.  A provider’s decision to prescribe 
oral PrEP involves sensitive, in-depth conversations with a patient about 
contraindications, history of risk-taking behavior, power dynamics in 
relationships and intimate partner abuse, consideration of the particular 
risk group to which the patient belongs, history of condom usage, and a 
number of other factors that may not be easily articulated to insurers by 
the physician and may not be reflected in medical literature.224  If insurers 
give due weight to the provider’s assessment of safety and appropriateness 
for the particular patient, it is likely that oral PrEP would satisfy this 
element of medical necessity definitions. 
iv. Convenience
Under common definitions of medical necessity, a convenience element 
helps insurers weed out prescribed treatments that are not medical in 
nature, are meant primarily for the “comfort”225 or convenience of the 
patient or the provider, constitute “luxuries,”226 or result from the patient’s 
“social or environmental” situation.227  Determinations of convenience are 
purportedly not based on the insurer’s perspective; they involve consideration 
of the insured’s and the provider’s perspectives.228 
Given that actual efficacy of condoms in practice is significantly lower 
than its ninety-five percent medical efficacy and that HIV rates have 
continued to rise in certain high-risk groups regardless of condom 
messaging, PrEP is more than a mere convenience for members of these 
communities; it is a medically necessary treatment.229  However, insurers 
 223.  See Liz Highleyman, AHF PrEP Ad Controversy: What Do the Numbers 
Mean?, BETA BLOG, Sept. 2, 2014, http://betablog.org/ahf-prep-ad-controversy-numbers-
mean [http://perma.cc/37PN-USPH]. 
 224.  See CDC PrEP Research Summary, supra note 57. 
 225.  KAISER PLAN, supra note 196, at 38, 40, 42 (excluding “[c]omfort, convenience, 
or luxury equipment or features”). 
 226.  Id. at 38. 
 227.  Rosenbaum, supra note 185, at 13. 
 228.  See id.; e.g., UHA, supra note 196, at 1 (“Not primarily for . . . the convenience 
of the patient, treating physician, or other health care provider.”). 
 229.  See Matt Baume, Does Hobby Lobby Have To Pay for My PrEP?, ADVOCATE 
(Oct. 27, 2014, 7:00 AM), http://www.advocate.com/31-days-prep/2014/10/27/does-
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could argue that because Truvada as PrEP is primarily marketed and CDC 
recommended as an extra layer of protection in addition to condoms, it is 
unnecessary care because condoms are technically medically effective. 
Furthermore, if insurers, particularly religiously affiliated issuers, accept 
the notion that PrEP is a nonessential treatment meant to facilitate the 
preferred lifestyle choices of individuals seeking to engage in the pleasure 
of condomless sex or other high-risk conduct, such insurers may be less 
willing to cover PrEP treatment, even when the patient and provider both 
believe it is necessary care.230  High-risk patients who believe their denials 
are the result of discrimination would probably not be able to rely on the 
ACA’s nondiscrimination provision, Section 1557, because those seeking 
PrEP are not HIV positive.231 
Each element of modern medical necessity clauses presents a different 
challenge for those seeking to prevent benefit denials.  A further complicating 
factor vis-à-vis medical necessity is the variation in coverage determination 
processes across the industry and the lack of transparency.  Utilization 
review practices vary widely from insurer to insurer, and insurers provide 
hobby-lobby-have-pay-my-prep [http://perma.cc/PVB9-5XR8] (quoting Scott Schoettes, 
HIV Project Director at Lambda Legal, who emphasized that PrEP “is medically necessary 
care”). 
 230.  In scenarios when condoms cannot be used as a primary line of defense, the 
insured would have a strong argument that PrEP is not a convenience treatment.  For 
example, condoms cannot be used in the context of heterosexual serodiscordant couples 
attempting to reduce the risk of transmission to the fetus during conception and childbirth.  
See Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women 
for Maternal Health and Interventions To Reduce Perinatal HIV Transmission in the 
United States, AIDSINFO, http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/153/ 
reproductive-options-for-hiv-concordant-and-serodiscordant-couples [http://perma.cc/Q7W7- 
LPVA] (last updated Mar. 28, 2014).  Condoms also cannot be used in the case of 
individuals with latex allergies.  See Latex and Contraception, AM. LATEX ALLERGY
ASS’N, http://latexallergyresources.org/articles/latex-and-contraception [http://perma.cc/ 
4VXF-JWNY] (last visited Mar. 25, 2015). 
 231.  See 42 U.S.C. § 300gg-5 (2012).  Those experiencing discrimination in healthcare 
because of their HIV-positive status may seek protection of the ACA’s antidiscrimination 
provision because this section prohibits discrimination based upon disability.  See id. 
However, those taking PrEP are not infected and, hence, not disabled as a result of the 
HIV status.  An argument that the benefit denial is a result of discrimination based upon 
the patient’s sexual orientation would also likely fail because, as it stands, the section does 
not include discrimination based upon sexual orientation.  See Ronald O. Valdiserri, 
Presentation at the Office of HIV/AIDS and Infectious Disease Policy of the U.S. 
Department of Health and Human Services: The ACA and LGBT Individuals: Delivering 
Culturally Competent Quality Care in Clinical Settings (May 20, 2014), https://www. 
aids.gov/pdf/aca-lgbt-individuals.pdf [https://perma.cc/NL4U-STWS]. 
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little information to the public.  The ACA has done little to regularize the 
prior authorization process or to establish common medical necessity 
definitions.232  However, advocates could seek regulatory guidance that 
would help streamline utilization review across the industry, gain 
transparency, and help prevent future benefit denials. 
IV. PREP IN THE POST-HEALTH REFORM LANDSCAPE
One potential solution to overcoming the multidimensional acceptability 
and accessibility challenges to fuller implementation of PrEP is health 
content regulation.  This is only one piece of the puzzle, however; I do not 
argue that mandating benefits is the only answer, or even the best answer, 
to the problems advocates face in scaling up PrEP.  However, mandating 
benefits would be a step toward gaining acceptability for and securing 
access to oral PrEP prevention.  Given that full implementation of the 
ACA occurred this past year, I first examine whether there are any 
mechanisms to ensure access to PrEP under the ACA.233 
President Barack Obama signed the ACA on March 23, 2010.234  
Preliminary data shows that the ACA is having a remarkable impact on 
access to more affordable treatment for Americans,235 including HIV-
positive individuals.236  By eliminating the preexisting condition requirement, 
 232.  See B. Jessie Hill, What Is the Meaning of Health? Constitutional Implications 
of Defining “Medical Necessity” And “Essential Health Benefits” Under the Affordable 
Care Act, 38 AM. J.L. & MED. 445, 450 (2012). 
 233.  See Health Reform Implementation Timeline, KAISER FAM. FOUND., 
http://kff.org/interactive/implementation-timeline (last visited Mar. 25, 2015) (detailing 
the provisions that took effect on January 1, 2014). 
 234.  Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, 124 
Stat. 119 (codified as amended in scattered section of 42 U.S.C.).  The President then 
signed The Health Care and Education Reconciliation Act of 2010 (HCERA) on March 
30, 2010, which amended provisions of the ACA.  Health Care and Education 
Reconciliation Act of 2010, Pub. L. No. 111-152, 1124 Stat. 1029 (2010).  References to 
the ACA in this Article refer to the ACA as amended by the HCERA.  See Kyle Pettersen-
Scott, Comment, Prevent More, Spend More, Be Well: The Impact of the Affordable Care 
Act’s Provisions Regarding Preventive Care Coverage, Minimum Medical Loss Ratios, 
and Wellness Programs, 4 N.C. CENT. U. BIOTECHNOLOGY& PHARMACEUTICAL L. REV. 
26, 26 (2011). 
 235.  Micah L. Berman, A Public Health Perspective on Health Care Reform, 21 
HEALTH MATRIX 353, 353 (2011). 
 236.  See Affordable Care Act and Its Impact on People Living with HIV/AIDS, AIDS 
ACTION COMMITTEE, http://www.aac.org/media/blog/affordable-care-act-and-its-impact.html 
(last updated Oct. 1, 2013); The Affordable Care Act and HIV/AIDS, AIDS.GOV (Nov. 21, 
2014), http://aids.gov/federal-resources/policies/health-care-reform [http://perma.cc/ZJ49-T9L8]; 
Jennifer Kates & Rachel Garfield, The ACA and People with HIV: The ACA’s Impact and 
the Implications of State Choices, HEALTH AFFAIRS BLOG (Mar. 3, 2014, 4:05 PM), 
http://healthaffairs.org/blog/2014/03/03/the-aca-and-people-with-hiv-the-acas-impact-and-the-
implications-of-state-choices [http://perma.cc/2PHS-DSH3]. 
[VOL. 52:  171, 2015] When Condoms Fail 
SAN DIEGO LAW REVIEW 
215 
the ACA has the potential to decelerate the spread of HIV by helping HIV-
positive individuals gain access to ARVs and lower the virus’s 
communicability.237  In addition to securing healthcare for HIV-positive 
individuals, the ACA has the potential to be a game-changer in the HIV 
prevention context.  For example, the ACA requires that insurers offer 
free HIV testing to at-risk individuals.238  One analysis concluded that 
approximately 500,000 people might be tested over the next two years in 
connection with this requirement.239  If more states expand Medicaid,240 
this number could rise dramatically.  Researchers estimate that in the 
event all states expand Medicaid, HIV testing and diagnosis may increase 
thirty percent more, to over 1,103,024 people.241  A significant increase in 
cost-free testing could lead to an increase in early HIV diagnosis, treatment, 
and viral suppression.  As such, the impact on HIV incidence at the 
population level could be substantial. 
Beyond facilitating greater access to HIV testing, how might the ACA’s 
mandates affect the implementation of PrEP prevention?  Does the ACA 
help resolve or further frustrate the acceptability and accessibility challenges 
to fuller implementation?  In this Part, I consider the ACA’s PSP, and the 
possibility of federal action under the EHBP. 
A.  The ACA’s Preventive Services Provision 
Title I of the ACA, which relates to health insurance access, contains a 
mandate requiring health insurers to provide cost-free access to certain 
preventive health services.242  This section is often referred to as the 
 237.  See 42 U.S.C. § 300gg-3 (2012). 
 238.  See infra notes 276–277 and accompanying text. 
239.  Zachary Wagner et al., The Affordable Care Act May Increase the Number of 
People Getting Tested for HIV by Nearly 500,000 by 2017, 33 HEALTH AFFAIRS 378, 382 
(2014). 
 240.  As of this writing, twenty-eight states and the District of Columbia are expanding 
Medicaid, nineteen states have not expanded Medicaid, and three have not yet made a 
decision.  A 50-State Look at Medicaid Expansion, FAMILIES USA, http://families usa.org/ 
product/50-state-look-medicaid-expansion-2014 [http://perma.cc/D58C-CEK4] (last updated 
Nov. 24, 2014); see also Medicaid Expansion & What It Means for You, HEALTHCARE.
GOV, https://www.healthcare.gov/medicaid-chip/medicaid-expansion-and-you/ [https://perma.cc/ 
98W8-VLHN] (last visited Mar. 25, 2015) (noting that some states are expanding their 
Medicaid programs whereas others are not). 
 241.  See Wagner, supra note 239, at 378, 382. 
242.  42 U.S.C. § 300gg-13 (2012). 
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“preventive services” provision (PSP).243  The PSP requires that group 
health insurance plans and insurance issuers that are not grandfathered 
cover certain preventive services without cost sharing.244  This means that 
recommended preventive services must be offered cost-free for those 
carrying nongrandfathered commercial insurance.245  The ACA neither 
specifically defines covered services nor designates categories of covered 
services in this provision.  Rather, Congress outsourced this determination. 
Under the PSP, preventive services offered cost-free must include 
“[e]vidence-based items or services that have in effect a rating of ‘A’ or 
‘B’ in the current recommendations of the United States Preventive 
Services Task Force.”246 
The USPSTF, originally convened in 1984 under the title “U.S. Public 
Health Service,”247 was established under the ACA for the purpose of 
“review[ing] the scientific evidence related to the effectiveness, 
appropriateness, and cost-effectiveness of clinical preventive services.”248  
The Task Force consists of a “panel of non-Federal experts” in the areas 
of “prevention and evidence-based medicine” and is composed of “primary 
care providers.”249  This body represents the gold standard in preventive 
medicine guidance and its recommendations are intended for an audience 
of primary care physicians.250  The USPSTF contains sixteen volunteer 
 243.  See Cogan, supra note 165, at 356–57. 
 244.  42 U.S.C. § 300gg-13.  According to Healthcare.gov, a federal government 
website managed by the U.S. Centers for Medicare & Medicaid Services, cost sharing is 
the share of total costs, including copayments, deductibles, coinsurance, but not premiums, 
covered by the insurer that is paid by the insured.  Cost Sharing, HEALTHCARE.GOV, 
https://www.healthcare.gov/glossary/cost-sharing [https://perma.cc/A5VA-9EVY] (last 
visited Mar. 25, 2015). 
 245.  See Berman, supra note 235, at 369. 
246.  42 U.S.C. 300gg-13(a)(1). 
247.  Solicitation for Nominations for Members of the U.S. Preventive Services Task 
Force (USPSTF), 79 Fed. Reg. 14,045 (Mar. 12, 2014). 
 248.  42 U.S.C. § 299b-4(a)(1) (2012); see also Amanda Cassidy, Health Policy 
Brief: Preventive Services Without Cost-Sharing, HEALTH AFFAIRS 2–3 (Dec. 28, 2010), 
http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_37.pdf 
[http://perma.cc/FLM9-RNYE] (“When analyzing a particular preventive service, the 
USPSTF estimates the benefits and harms based on a review of the clinical evidence.”). 
 249.  Newsroom, U.S. PREVENTIVE SERVICES TASK FORCE (Jan. 2015), http://www. 
uspreventiveservicestaskforce.org/Page/Name/newsroom [http://perma.cc/WY9H-VNHL]. 
 250.  About the USPSTF, U.S. PREVENTIVE SERVICES TASK FORCE (Sept. 2014) 
http://www.uspreventiveservicestaskforce.org/about.htm [http://perma.cc/KM7B-74AA]; 
see also Berman, supra note 235, at 369 (noting all private health insurance carriers are 
required to provide full coverage for clinical preventive services recommended by the 
USPSTF (citing 42 U.S.C. 300gg-13)); Davis & Somers, supra note 144, at 66 (noting the 
USPSTF reviews the evidence base for preventive services and develops recommendations for 
the health care community); Pettersen-Scott, supra note 234, at 31 (discussing that the 
USPSTF is intended to provide primary care physicians with evidence-based information 
to aid in providing preventive services to their patients). 
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members serving four-year terms.251  The ACA requires that Task Force 
members are “independent and, to the extent practicable, not subject to 
political pressure.”252  Anyone may nominate a Task Force member, and 
nominations and applications are only viewable in person at the Agency 
for Healthcare Research and Quality’s (AHRQ) Center for Primary Care, 
Prevention, and Clinical Partnerships.253  Stated qualifications for members 
are “knowledge, expertise, and leadership” in evaluation of research, clinical 
prevention and primary care, and implementation of recommendations in 
clinical practice.254  Additionally, the AHRQ seeks members who have 
expertise in the following areas: (1) public health and reduction of health 
disparities, (2) women’s health, and (3) health issues affecting minorities.255 
Duties of the Task Force include developing recommendations for the 
healthcare community,256 developing topics for recommendations,257 
reviewing previous recommendations,258 providing assistance to healthcare 
professionals,259 and submitting yearly reports to Congress identifying 
gaps in research and recommending “priority areas . . . related to populations 
and age groups not adequately addressed by current recommendations.”260 
Each recommendation issued by the Task Force, called a 
“Recommendation Statement,” receives an A, B, C, D, or I rating “based 
on the strength of the evidence and the balance of benefits and harms of a 
preventive service.”261  Prior to issuing a final recommendation, the Task 
Force first drafts a research plan “that guides the recommendation 
process” and seeks public comment before issuing a final research plan.262  
 251.  VIRGINIA MOYER ET AL., U.S. PREVENTIVE SERVS. TASK FORCE, HIGH-PRIORITY 
EVIDENCE GAPS FOR CLINICAL PREVENTIVE SERVICES: THIRD ANNUAL REPORT TO CONGRESS 3
(2013), http://www.uspreventiveservicestaskforce.org/annlrpt3/ annlrpt2013.pdf. 
252.  42 U.S.C. § 299b-4(a)(6) (2012). 
 253.  Solicitation for Nominations for Members of the U.S. Preventive Services Task 
Force (USPSTF), 79 Fed. Reg. 14,045 (Mar. 12, 2014). 
 254.  Id. 
 255.  See id. 
256.  42 U.S.C. § 299b-4(a)(1) (2012). 
257.  42 U.S.C. § 299b-4(a)(2)(A) (2012). 
258.  42 U.S.C. § 299b-4(a)(2)(B) (2012). 
259.  42 U.S.C. § 299b-4(a)(2)(E) (2012). 
260.  42 U.S.C. § 299b-4(a)(2)(F) (2012); see, e.g., USPSTF 2013 Annual Report, 
supra note 251. 
 261.  About the USPSTF, supra note 250. 
 262.  Recommendations in Progress, U.S. PREVENTIVE SERVICES TASK FORCE (NOV.
2014), http://www.uspreventiveservicestaskforce.org/Page/Name/topics-in-progress [http:// 
perma.cc/ZTA3-W2K8]. 
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The Task Force then drafts an evidence report and a recommendation, for 
which it also seeks public comment, before issuing a final evidence report 
and recommendation statement.263  Comments are not made widely available 
to the public in electronic format. 
As the Task Force considers a preventive treatment, it conducts a 
balancing of benefits versus harms.264  Among the five ratings, a rating of 
A or B indicates the health benefits “substantially outweigh [the] harms.”265  
For preventive measures garnering these ratings, the USPSTF recommends 
clinicians offer the service and that patients partake.266  According to the 
PSP, covered insurers must offer A and B recommended services at no 
cost to the insured.267  Recommendations rated C indicate the Task Force 
has found the “net benefit is small,” and providers should “selectively 
offer[] . . . [the prevention] to individual patients based on professional 
judgment and patient preferences.”268  Recommendations rated D indicate 
the preventive service “has no net benefit or that the harms outweigh the 
benefits.”269  Finally, a rating of I indicates evidence is “insufficient to 
assess the balance of benefits and harms.”270  Under the PSP, insurers are 
under no obligation to cover services or treatments garnering C, D, or I 
recommendations.271 
 263. Id.  Since 2010, the Task Force has sought public comment on forty-seven draft 
research plans and recommendations.  Opportunity for Public Comment, U.S. PREVENTIVE 
SERVICES TASK FORCE (Nov. 2014), http://www.uspreventiveservicestaskforce.org/Page/ 
Name/us-preventive-services-task-force-opportunities-for-public-comment [http://perma. 
cc/3UG6-ELHA]; Published Recommendations, U.S. PREVENTIVE SERVICES TASK FORCE 
(Mar. 2015), http://www.uspreventiveservicestaskforce.org/BrowseRec/Index [http://perma. 
cc/97NQ-B7VH]. 
 264.  According to the USPSTF, the potential benefits of preventive services may 
include “reduction of risk factors to prevent disease, early identification of disease leading 
to earlier treatment, and, ultimately, improved health outcomes such as quality of life and 
length of life.”  MOYER ET AL., supra note 251, at 5.  Conversely, the potential harms of 
preventive services may include adverse effects, side effects, and treatment complications, 
in addition to the harms of “inaccurate test results that may lead to a cascade of additional 
followup tests (some of which are invasive and could cause harm) and unnecessary 
treatments.”  Id.  The USPSTF may also consider “the benefits and harms based on age, 
sex, and risk factors for the disease” when appropriate evidence exists.  Id.  The USPSTF 
states that it “does not explicitly consider costs in its appraisal of the effectiveness of a 
service[,]” id. (emphasis added), but this implies that the USPSTF may consider costs off 
the record. 
 265.  Id. 
 266.  Id. 
267.  42 U.S.C. 300gg-13(a)(1) (2012). 
 268.  Grade Definitions, U.S. PREVENTIVE SERVICES TASK FORCE (Feb. 2013), 
http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm [http://perma.cc/66EM-
M8N6]. 
 269.  Id. 
 270.  Id. 
 271.  See 42 U.S.C. 300gg-13(a)(1). 
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As of this writing, the Task Force has issued draft or final 
recommendations on ninety-eight topics.272  Of these, fifty-five evidence-
based preventive services or treatments have received A or B 
recommendations.273  Of these fifty-five services, six recommendations 
are pharmacological preventions.274  Most, though not all, of the 
pharmacological preventions recommended for use with A and B ratings 
are vitamins, supplements, or over-the-counter pain relievers such as 
aspirin.275  The USPSTF has only issued two recommendations pertaining 
 272.  Published Recommendations, supra note 263. 
 273.  USPSTF A and B Recommendations, U.S. PREVENTIVE SERVICES TASK FORCE
(Oct. 2014), http://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-a-and-b-
recommendations/ [http://perma.cc/D43D-5AWG]. 
 274.  See id.  Three of these pharmacological prevention recommendations pertain to 
aspirin.  See id. 
 275.  First, the USPSTF has given a B recommendation to tamoxifen or raloxifene 
for women at risk of primary breast cancer, and a D recommendation to the same 
medication for women not at risk.  Breast Cancer: Medications for Risk Reduction, U.S.
PREVENTIVE SERVICES TASK FORCE (Sept. 2013), http://www.uspreventiveservicestask 
force.org/uspstf13/breastcanmeds/breastcanmedsrs.htm [http://perma.cc/4PS4-KCQS]. 
Second, a combination of exercise or physical therapy and vitamin D supplementation for 
people at risk of falls received a B rating from the USPSTF.  Vitamin D and Calcium To 
Prevent Fractures: Preventive Medication, U.S. PREVENTIVE SERVICES TASK FORCE (Sept. 
2013), http://www.uspreventiveservicestaskforce.org/uspstf12/vitamind/ finalrecvitd.htm 
[http://perma.cc/5GPX-TJZJ].  Third, the USPSTF gave an A rating to the recommendation of 
folic acid for all women planning or capable of pregnancy to prevent certain birth defects.  
Folic Acid to Prevent of Neural Tube Defects: Preventive Medication, U.S. PREVENTIVE 
SERVICES TASK FORCE (Sept. 2013), http://www.uspreventiveservicestaskforce.org/uspstf09/ 
folicacid/folicacidrs.htm [http://perma.cc/K59F-8DDQ].  Fourth, the USPSTF issued an 
A recommendation for the prescription of prophylactic ocular topical medication for all 
newborns for the prevention of neonatal conjunctivitis.  Ocular Prophylaxis for 
Gonococcal Ophthalmia Neonatorum: Preventive Medication, U.S. PREVENTIVE SERVICES
TASK FORCE (Sept. 2013), http://www.uspreventiveservicestaskforce.org/uspstf10/gono 
culproph/ gonocup.htm [http://perma.cc/BZ8H-MSM2].  Finally, a recommendation for 
low-dose aspirin for the prevention of preeclampsia in pregnant women received a 
preliminary rating of B from the USPSTF.  Low-Dose Aspirin for the Prevention of 
Morbidity and Mortality from Preeclampsia: Preventive Medication, U.S. PREVENTIVE
SERVICES TASK FORCE (Sept. 2014), http://www.uspreventiveservicestaskforce.org/uspstf/ 
uspsaspg.htm [http://perma.cc/5V59-DZ4J].  Of the other final preventive medication 
recommendations not garnering an A or B recommendation, aspirin received a D 
recommendation for the prevention of colorectal cancer.  Final Recommendation Statement: 
Aspirin/NSAIDs for Prevention of Colorectal Cancer: Preventive Medication, U.S. 
PREVENTIVE SERVICES TASK FORCE (Mar. 2007), http://www.uspreventiveservicestask 
force.org/Page/Document/RecommendationStatementFinal/aspirin-nsaids-for-prevention-of-
colorectal-cancer-preventive-medication [http://perma.cc/98YV-48EU].  In addition, the 
Task Force ascribed a D rating to the use of combined estrogen and progestin for the 
prevention of chronic conditions in postmenopausal women and women who have had a 
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to HIV prevention.  The Task Force recommends HIV screening for all 
adolescents and adults ages fifteen to sixty-five years old and all individuals 
at increased risk (rated A), as well as screening for all pregnant women, 
both those untested and in labor, and those whose HIV status is not known 
(both rated A).276  As such, covered insurers must offer HIV testing cost-
free for those fitting these clinical profiles.  According to the Task Force’s 
website, no further recommendations pertaining to HIV are currently 
under consideration.277 
With the passage of the ACA’s PSP, the USPSTF has become the sole 
body that determines preventive healthcare for millions of Americans.  Its 
recommendations not only affect private insurers covered under the 
provisions but also governmental insurers such as Medicare278 and 
Medicaid.279  As such, the impact of a USPSTF A or B recommendation 
hysterectomy, thereby recommending against its use.  Menopausal Hormone Therapy: 
Preventive Medication, U.S. PREVENTIVE SERVICES TASK FORCE (Sept. 2013), http:// 
www.uspreventiveservicestaskforce.org/uspstf/uspspmho.htm [http://perma.cc/7URM-
5FSF].  Finally, the Task Force recommended against the use of Vitamin D for the prevention 
of fractures and vitamin E for the prevention of cardiovascular disease.  These received a 
rating of D and I (inconclusive), respectively.  Vitamin Supplementation To Prevent Cancer 
and CVD: Counseling, U.S. PREVENTIVE SERVICES TASK FORCE (Feb. 2014), http:// 
www.uspreventiveservicestaskforce.org/uspstf14/vitasupp/vitasuppfinalrs.htm [http://perma. 
cc/VSV7-K4JR]. 
 276.  MOYER ET AL., supra note 251, at 9, 25. 
 277.  Published Recommendations, supra note 263. 
278.  Medicare is “the largest payer for health services for American adults.”  Lesser 
et al., supra note 154, at 44.  The ACA specifically requires that Medicare cover all 
preventive services with A or B recommendations without cost-sharing.  See Lynda 
Flowers & Lynn Nonnemaker, Improvements to Medicare’s Preventive Services Under 
Health Reform, AARP PUB. POL’Y INST. 1 (2010), http://assets.aarp.org/rgcenter/ppi/ 
health-care/fs180-preventive.pdf [http://perma.cc/N5PJ-7E7R].  Because the ACA has 
caused Medicare preventive services to track USPSTF recommendations, a USPSTF 
recommendation directly impacts whether Medicare will cover a specific prevention cost-
free. 
 279.  Under the ACA, A or B recommendation from the Task Force affects access to 
free preventive care for Medicaid beneficiaries.  The federal government pays states with 
existing Medicaid programs an additional one percent in matching funds to cover costs of 
the A and B recommended preventive services they offer cost-free.  See Cogan, supra note 
165, at 357.  Advocates have called this a “strong financial incentive for states to provide 
[preventive care] without cost-sharing.”  Id.  In addition, states expanding their Medicaid 
programs must offer all USPSTF A and B recommendations without cost-sharing.  See 
Lindsey Dawson, Pub. Policy Assoc., The AIDS Inst., Presentation at the United States 
Conference on AIDS: The Impact of the ACA and USPSTF Grade Change on Coverage 
of HIV Testing (Sept. 9, 2013), www.theaidsinstitute.org/sites/default/files/attachments/Testing 
_Dawson%20USCA%202013.pdf [http://perma.cc/9G3K-U963].  One expert has even 
predicted that as a result of the change to a uniform set of preventive care standards in 
Medicare and Medicaid, ninety-five percent of all nonelderly U.S. residents could receive 
preventive care coverage with no cost-sharing by 2016.  See Cogan, supra note 165, at 357 
(citing CBO’s March 2011 Estimate of the Effects of the Insurance Coverage Provisions 
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for Truvada as PrEP would be wide reaching.  An A or B recommendation 
from the Task Force would effectively provide cost-free access to Truvada 
as PrEP for beneficiaries of most private and all governmental healthcare 
issuers.  This would have a significant impact on utilization of PrEP, as 
offering PrEP cost-free creates a financial incentive for all high-risk 
individuals to ask their healthcare providers about it.280  Cost-free access 
to PrEP would especially impact utilization by high-risk individuals of 
low socioeconomic status, such as young MSM, intravenous drug users, 
and sex workers. 
In addition, an A or B recommendation for PrEP would be a substantial 
step toward making PrEP more acceptable to high-risk communities, as 
the widespread availability and greater utilization of PrEP will help 
eliminate stigma, and to healthcare providers who might use the 
recommendation as a means of introducing PrEP as an option for patients 
who fit the clinical profile.  An A or B rating for PrEP would also align 
the USPSTF with the CDC guidance, which may increase the legitimacy 
of PrEP as HIV prevention in the minds of providers.  Furthermore, such 
a rating would combat individual and structural stigma, as universal 
coverage for PrEP would likely require coding and billing changes and 
help change traditional assumptions about HIV prevention. 
Despite the wide-ranging positive impact an A or B recommendation 
for PrEP would have on implementation efforts, a favorable recommendation 
for PrEP may not be possible without limiting the scope of the 
recommendation to certain clinical profiles.  There are at least three 
reasons for this.  First, in light of the backlash in the medical community 
that has resulted from recommendations for politically neutral treatments,281 
Contained in the Patient Protection and Affordable Care Act (Public Law 111-148) and 
the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152), CONG. BUDGET
OFF. (Mar. 18, 2011), http://www.cbo.gov/ sites/default/files/HealthInsuranceProvisions_1.pdf 
[http://perma.cc/EPA4-65MN]). 
 280.  Cf. Cogan, supra note 165, at 356–57. 
 281.  In the post-health reform environment, even seemingly politically neutral 
preventions that receive a negative recommendation have engendered debate in both the 
medical and public health communities due to the recommendation’s impact on access to 
healthcare nationwide.  See Berman, supra note 235, at 373 (“The general reaction to the 
USPSTF’s recommendations . . . range[] from confusion to intense anger.”); see, e.g., 
Bradley Anderson, Scared of Obamacare’s IPAB? Meet the USPSTF!, AM. SPECTATOR 
(Feb. 27, 2013), http://spectator.org/articles/33836/scared-obamacares-ipab-meet-uspstf 
[http://perma.cc/BCH5-VL44].  For example, the Task Force issued a C recommendation 
for annual mammograms for women between the ages of forty and forty-nine.  This rating, 
effectively meaning that the measure should be “selectively” offered to patients based on 
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it stands to reason that the Task Force would proceed cautiously with 
respect to PrEP, which generates controversy even in the high-risk groups 
who stand to benefit from the prevention.  PrEP used in the context of 
certain clinical profiles, such as in the context of monogamous, 
serodiscordant couples trying to conceive, may be less controversial than 
in other contexts.  Even the AHF, one of the biggest opponents to broader 
PrEP rollout, has recommended PrEP in this context.282  Second, the Task 
Force may perceive that the cost-benefit analysis more clearly supports a 
positive recommendation for PrEP in certain clinical profiles.  Again in 
the context of heterosexual serodiscordant couples using PrEP during 
conception attempts, concern about the impact of risk compensation is 
reduced.  In addition, the risk of long-term side effects and concern about 
viral resistance and long-term adherence are lessened because the HIV-
negative female in this context may only undergo PrEP treatment for a 
finite period of time—before and during pregnancy—whereas PrEP 
prevention in other risk groups requires treatment in perpetuity.283  Finally, 
PrEP treatment comes at a significant cost, and mandating widespread 
cost-free coverage across all risk groups may not be economically 
professional judgment and patient wishes, was met with a great deal of resistance by the 
medical community.  See, e.g., Berman, supra note 235, at 371–74; Harold Pollack, Health 
Reform and Public Health: Will Good Policies but Bad Politics Combine To Produce Bad 
Policy?, 159 U. PA. L. REV. 2061, 2068 (2011); Ben Hartman, How ACA May Impact 
Preventive Care, EVERYDAY HEALTH (Nov. 13, 2013), http://www.everydayhealth. 
com/columns/ben-hartman-healthcare-reform-and-you/how-aca-may-impact-preventive-
care [http://perma.cc/UK6T-Z7X8]; Emily P. Walker, AMA Bucks USPSTF on Mammography, 
ABCNEWS (June 19, 2012), http://abcnews.go.com/ Health/ama-bucks-uspstf-mammography/ 
story?id=16605261 [http://perma.cc/AD9F-N3F9]. 
 282.  See text accompanying note 101. 
 283.  See PrEP for HIV Prevention, supra note 13. 
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feasible.284  In the pregnancy context, however, issues of cost are lessened 
because treatment is finite.285 
There are at least two drawbacks to this incremental approach.  First, 
seeking cost-free access for one select group that comprises a small 
percentage of the high-risk pool may have little effect on wider implementation 
and HIV incidence rates at the population level.  Second, focusing on 
heterosexual serodiscordant couples to the derogation of other risk groups 
has the potential to further marginalize minority populations, such as the 
LGBT community, with unique health needs about which the medical 
community has been skeptical in the past.  Nonetheless, should the Task 
Force grant a favorable recommendation for PrEP in the context of 
heterosexual serodiscordant relationships, this could increase the acceptability 
of PrEP and engender a broader PrEP mandate under the PSP in the future. 
Regardless of the scope of a PrEP recommendation, advocates should 
work toward effectuating Task Force reform.  Systemic changes to the 
Task Force are needed to place checks upon an organization that under 
the ACA now acts under color of federal law.  Furthermore, because the 
USPSTF has the power under the ACA to directly impact access to 
preventive services for millions of Americans, its members are susceptible 
to the influence of special interests, including the health insurance 
industry.286  In fact, Congress appeared to recognize this concern in the 
text of the ACA itself, as evidenced by the requirement that Task Force 
members are “independent and, to the extent practicable, not subject to 
 284.  There are currently no Task Force recommendations mandating cost-free 
coverage for medications as costly as Truvada, for which there is no generic equivalent.  
See supra note 70 and accompanying text.  Tamoxifen, which received a B recommendation 
for women at risk of breast cancer, is available in generic form and costs approximately 
$100 per month.  Alicia Ault, Will 100% Coverage Spur More Use of Breast Cancer 
Chemopreventives?, ONCOLOGY PRAC. (Jan. 22, 2014), http://www.oncologypractice.com/single 
-view/will-100-coverage-spur-more-use-of-breast-cancer-chemopreventives/0887cd67af911 
c29b8a1db55b812d0b3.html [http://perma.cc/95H3-QF59]; Facts for Life: Tamoxifen, 
SUSAN G. KOMEN FOR CURE 2 (last visited Mar. 25, 2015), http://ww5.komen.org/ 
uploadedFiles/Content_Binaries/806-326a.pdf [http://perma.cc/WQV4-LH97]; see also 
Rita Rubin, Raloxifine or Tamoxifen: Which Is the Right Drug for You?, USA TODAY (Apr. 
17, 2006, 10:01 PM), http://usatoday30.usatoday.com/news/health/2006-04-17-q-and-a-
drug_x.htm [http://perma.cc/WXN7-ADPZ] (noting that, according to the National 
Cancer Institute, the average cost of the generic form of tamoxifen is approximately $100).  
The average cash price of Truvada is over $1000 per month.  See supra note 156 and 
accompanying text. 
 285.  See PrEP for HIV Prevention, supra note 13. 
 286.  See text accompanying supra note 252. 
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political pressure.”287  Those seeking Task Force reform should advocate 
for more transparency.  This could be achieved by pushing for (1) a more 
transparent appointment process by making nominations and applications 
more widely available and holding public appointment hearings, (2) 
publication of comments on draft recommendations through a more formal 
notice and comment procedure, (3) hearings on draft recommendations, and 
(4) further limitations on member service.  Such reforms could potentially be 
achieved through HHS regulation, executive order, or congressional act. 
In addition, the Task Force should be encouraged to broaden the scope 
of the “special populations” it considers.288  At this time, special populations 
include only two groups: (1) children and adolescents, and (2) older adults.289  
The Task Force should commit to developing preventive care 
recommendations pertaining to the primary care of members of minority 
populations, such as LGBT individuals, whose preventive care needs may 
be different from those of the general population.  Broadening the Task 
Force’s duties to include consideration of minority populations could be 
achieved through regulation.  For example, HHS could provide guidance 
as to what groups special populations should include. 
B.  The ACA’s Essential Health Benefits Provision 
The second major provision of the ACA affecting preventive healthcare 
is what is often referred to as the “essential health benefits” provision 
(EHBP).290  Starting in 2014, the ACA mandates coverage of “essential 
health benefits” in state health insurance exchanges, which includes states 
opting to expand their Medicaid programs.291  In the exchanges, this 
mandate applies to individual and small group plans.292  All must offer a 
package containing ten categories of services: 
[A]mbulatory patient services; emergency services; hospitalization; maternity 
and newborn care; mental health and substance use disorder services, including 
behavioral health treatment; prescription drugs; rehabilitative and habilitative 
services and devices; laboratory services; preventive and wellness services and 
287.  42 U.S.C. §299b-4(a)(6) (2012) (emphasis added). 
 288.  See Special Populations, U.S. PREVENTIVE SERVICES TASK FORCE (Aug. 2014), 
http://www.uspreventiveservicestaskforce.org/populations.htm [http://perma.cc/RH3X-XMZE]. 
 289.  Id. 
290.  42 U.S.C. § 18022 (2012). 
 291.  Id. § 18022(a)–(b). 
292.  42 U.S.C. § 18021 (2012). 
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chronic disease management; and pediatric services, including oral and vision 
care.293 
The ACA and the regulations promulgated thereunder do not specify 
what services must be covered by insurers in any required category.294  In 
fact, the ACA specifically forbids HHS from making “coverage decisions.”295  
Rather, individual coverage of specific preventions is to be determined at 
the state level.296  To effect this, HHS implemented a “benchmark plan” 
mechanism on January 1, 2014.297  States may select a benchmark plan 
from three of the largest plans operating in their state298 based upon 
standards established by regulation.299  The benchmark plan “serves as a 
reference plan” for other insurers operating in the state.300  Under the 
EHBP, all benchmark plans must cover preventive care301 and offer all of 
the cost-free services required under the PSP302 and any other services 
required by federal or state law.303  The benefits packages offered by 
insurers in the states covered by the EHBP must be “substantially equal” 
to benchmark plan benefits.304  Insurers may offer additional preventive 
services or may deny coverage for services not specifically required by 
federal or state law, as long as their plans remain substantially equal.305 
 293.  Id. § 18022(b)(1) (emphasis added); see Essential Health Benefits, HEALTH
CARE.GOV, https://www.healthcare.gov/glossary/essential-health-benefits [https://perma.cc/ 
J3SQ-QKE3] (last visited Mar. 25, 2015). 
 294.  E.g., 45 C.F.R. § 800.105 (2013). 
295.  42 U.S.C. § 18022 (b)(4)(B). 
 296.  E.g., CAL. CODE REGS. tit. 10, § 2594.3 (2014). 
297.  45 C.F.R. § 800.105(c). 
298.  45 C.F.R. §§ 156.100, 156.110 (2013).  States that do not select a benchmark 
plan are assigned the largest plan by enrollment within the state.  Id. § 156.100.  For a list 
of benchmark plans in all fifty states, see Additional Information on Proposed State 
Essential Health Benefits Benchmark Plans, CENTERS FOR MEDICARE & MEDICAID
SERVICES, http://www.cms.gov/CCIIO/Resources/Data-Resources/ehb.html [http://perma.cc/ 
Q7ZR-992D] (last visited Mar. 25, 2015). 
299.  45 C.F.R. § 800.105(c). 
 300.  CTR. FOR CONSUMER INFO. & INS. OVERSIGHT, ESSENTIAL HEALTH BENEFITS
BULLETIN 8 (2011), http://www.cms.gov/CCIIO/Resources/Files/Downloads/essential_ 
health_benefits_bulletin.pdf [http://perma.cc/EX2C-NNLZ]. 
 301.  See 42 U.S.C. § 18022(b)(1) (2012). 
302.  45 C.F.R. § 147.130 (2013). 
 303.  See Additional Information on Proposed State Essential Health Benefits Benchmark 
Plans, supra note 298. 
304.  45 C.F.R. § 800.105(b) (2013). 
 305.  See 45 C.F.R. § 147.130(a)(2) and the conclusion to example 4. 
226 
Because PrEP treatment is not a required benefit under the PSP or 
required under any federal or state law, benchmark plans that decide to 
cover PrEP do so on their own accord.  If they cover PrEP, it is likely that 
other exchange insurers operating in the state would follow suit. 
However, it is possible that other insurers in the state could decide not to 
cover PrEP at all.  Insurers who deny coverage outright could argue that 
denying coverage of PrEP for requesting beneficiaries, who likely 
comprise a small fraction of their member base, does not affect the value 
of the prevention package to members in their health plan as a whole. 
Thus, insurers could argue that essential health benefits offered continue 
to be substantially equal and actuarially equivalent to the benchmark 
plan’s package, even without PrEP coverage.  On the other hand, PrEP 
proponents could argue that, from the perspective of individual policy 
members whose plans reject their PrEP benefit requests, denying such 
benefits leaves their preventive care packages substantially unequal to 
benchmark plans that cover PrEP.  Alternatively, if some benchmark plans 
begin denying coverage for oral PrEP, this could lead to an onslaught of 
denials within those state exchanges.  Accordingly, it is possible that 
coverage of oral PrEP in the future could vary from insurer to insurer and 
from state to state, which could frustrate accessibility to PrEP and further 
complicate a large-scale rollout.  There are actions, however, that HHS 
could take to create some uniformity in how insurers determine coverage 
for PrEP. 
The ACA explicitly states HHS may not “make coverage decisions,” so 
it is unlikely HHS could mandate PrEP coverage as an essential health 
benefit through regulation.306  However, HHS may be able to promulgate 
regulations that would have the effect of streamlining the utilization 
review process for those seeking PrEP.  The ACA contains a provision 
that places some limitation on the Secretary’s ability to regulate the utilization 
review process: 
    Notwithstanding any other provision of the [ACA], nothing . . . shall be 
construed to—prohibit (or authorize the Secretary of Health and Human Services 
to promulgate regulations that prohibit) a group health plan or health insurance 
issuer from carrying out utilization management techniques that are commonly 
used as of [the date of enactment of the ACA].307 
The above limitation on the Secretary’s power to regulate utilization 
review contains several definitional ambiguities.  First, the ACA does not 
define “utilization management techniques,”308 and HHS could promulgate 
306.  42 U.S.C. § 18022(b)(4)(B) (2012). 
307.  42 U.S.C. § 18120(1) (2012). 
308.  Sara Rosenbaum et al., The Essential Health Benefits Provisions of the 
Affordable Care Act: Implications for People with Disabilities, COMMONWEALTH FUND 4 
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regulations defining the term.  Second, there is an open question as to 
which “commonly used” techniques HHS is actually barred from prohibiting, 
because the ACA also does not define that term.309  This, too, may be an 
appropriate subject for regulatory guidance.  Third, while this provision 
explicitly states HHS must not promulgate regulations that prohibit 
commonly used utilization management techniques, the provision does 
not forbid HHS from (a) promoting certain baseline utilization techniques, 
(b) regulating—though not prohibiting—the utilization techniques HHS 
determines are already “commonly used” in the industry, or (c) prohibiting 
utilization techniques HHS determines are not “commonly used” in the 
industry.310 
HHS could require that administrators reviewing prior authorization 
requests for medical necessity take into consideration the specific needs 
of high-HIV-incidence groups, such as the MSM group, which need other 
prevention options in light of the uptick of HIV incidence and the decrease 
of condom usage.  This would be a step toward a set of medical necessity 
standards that are tailored to specific minority populations and their 
unique healthcare needs.  Such action is supported by HHS’s broad 
discretion under the ACA to ensure nondiscrimination.311  In fact, the 
ACA explicitly states that the Secretary must “take into account the health 
care needs of diverse segments of the population, including women, 
children, persons with disabilities, and other groups.”312  Furthermore, 
HHS could add transparency to the process by requiring that insurers 
disclose more about their utilization review techniques. 
There would certainly be objections from healthcare issuers to these 
regulatory actions.  After all, insurers are protective of their own utilization 
review techniques and hostile to federal interference with a process that 
has historically been the province of healthcare providers.  Insurers could 
argue that the ACA provision limiting the Secretary’s power vis-à-vis 
utilization review expresses Congress’s intent to forbid the federal 
government from interfering in coverage determinations.  However, federal 
guidance pertaining to the utilization review process could increase 
(Mar. 2011), https://publichealth.gwu.edu/departments/healthpolicy/DHP_Publications/pub_ 
uploads/dhpPublication_E985318A-5056-9D20-3D44CD4E8D0F288B.pdf [https://perma. 
cc/XQA2-4HBL]. 
 309.  See 42 U.S.C. §18120(1). 
 310.  See id. 
311.  42 U.S.C. § 18022(b)(4)(A)–(C) (2012). 
312.  42 U.S.C. § 18022(b)(4)(C). 
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consumer awareness of coverage policies.  Indeed, in the context of PrEP, 
there is little information about insurers’ PrEP coverage policies across 
the industry.  Requiring disclosure of these policies would allow PrEP 
seekers to make more informed decisions about which insurer to choose—
if choice of insurer is even an option—and would give PrEP advocates a 
means of collecting information and detecting variations in oral PrEP 
coverage nationwide. 
C.  State Mandated Benefit Laws 
In addition to devising ways to ensure access to benefits for PrEP at the 
federal level, PrEP proponents should explore mandating benefits for 
PrEP at the state level through the passage of new mandated benefit laws 
and the amendment of existing ones. 
Mandated benefit laws are laws requiring state-licensed group health 
insurance plans to cover specific healthcare benefits in their plans.313  
These mandates generally do not apply to government payers, such as 
Medicare and Medicaid, or to self-insured employers who are exempt 
under the Employee Retirement Income Security Act.314  The purpose of 
a mandated benefit law is to provide access to treatments that employers 
might not choose to cover and to safeguard reimbursement for healthcare 
providers.315  Examples of benefits subject to state mandated benefit laws 
include treatments for autism,316 chiropractic therapy,317 breast 
reconstruction,318 certain cancer treatments in clinical trials,319 and off-
label use of prescription medication for the treatment of HIV/AIDS.320  
 313.  See SARA S. BACHMAN ET AL., COMPREHENSIVE REVIEW OF MANDATED
BENEFITS IN MASSACHUSETTS: REPORT TO THE LEGISLATURE 1 (2008), http://mass.gov/chia/ 
docs/r/pubs/mandates/comp-rev-mand-benefits.pdf [http://perma.cc/8DTE-W893]; Mariam J. 
Laugesen et al., A Comparative Analysis of Mandated Benefit Laws, 1949–2002, 41 
HEALTH SERVICES RES. 1081, 1083 (2006), http://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC1713218 [http://perma.cc/3S4J-LMS3]. 
 314.  BACHMAN, supra note 313, at 7 (citing Gail A. Jensen & Michael A. Morrisey, 
Employee-Sponsored Health Insurance and Mandated Benefit Laws, 77 MILBANK Q. 425, 
426 (1999)). 
 315.  Id. at 8 (citing Laugesen et al., supra note 313, at 1083–84). 
 316.  See Insurance Coverage for Autism, NAT’L CONF. ST. LEGISLATURES (Aug. 
2012), http://www.ncsl.org/research/health/autism-and-insurance-coverage-state-laws.aspx 
[http://perma.cc/H3VH-VYUU]. 
 317.  E.g., WASH. REV. CODE. ANN. § 48.43.045 (West 2008); WASH. ADMIN. CODE 
§ 284-43-205 (2014), http://app.leg.wa.gov/wac/default.aspx?cite=284-43-205 [http://perma.
cc/N6GE-VUEG]. 
 318.  E.g., CONN. GEN. STAT. ANN. § 38a-504c (West 2007). 
 319.  E.g., S.B. 409, 2000 Sess. (N.H. 2000). 
 320.  E.g., MASS. GEN. LAWS ch. 176, § 47P (2011).  For a state-by-state list of 
mandates, see Additional Information on Proposed State Essential Health Benefits Benchmark 
Plans, supra note 298. 
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Mandated benefit laws are not limited to treatment of illnesses, conditions, 
or diseases, however.  There are also numerous preventive services covered 
by mandated benefit laws, including prenatal HIV prevention, contraception, 
colorectal cancer screening, and genetic testing.321  In fact, across all 
mandated benefit laws, coverage of preventive care is the one of the most 
common types of mandated benefit.322 
There are several potential justifications for passing new mandated 
benefit laws for oral PrEP.323  If insurers begin to deny coverage for PrEP, 
the potential adverse impact on HIV prevention within the state may be a 
justification.324  The underutilization of PrEP as an HIV prevention tool 
in a state, especially when it could significantly reduce HIV incidence 
with a broader uptake, may also be a justification.325  Additionally, PrEP 
accessibility issues that are the result of some injustice within the 
healthcare industry, such as institutional and provider biases against PrEP, 
expensive specialty drug tiering of ARVs that steers away risk, or outright 
discriminatory practices, may also be a sufficient justification.326  
Furthermore, failures at the federal level, such as a negative USPSTF 
recommendation, legislative or regulatory inertia, or other health reform 
failures, might be a worthy justification for a state mandate.327  Finally, a 
favorable cost-benefit financial analysis for PrEP would also justify 
required coverage.328 
A state-mandated benefit for PrEP would enable greater access to the 
treatment and could generate more meaningful conversations between 
 321.  See Laugesen et al., supra note 313, at 1087–88. 
 322.  As of 2002, there were 295 laws pertaining to preventive care, which covered a 
range of seventeen benefits.  See id. at 1081. 
 323.  See Amy B. Monahan, Value-Based Mandated Health Benefits, 80 U. COLO. L.
REV. 127, 127 (2009) (arguing that mandated benefit laws must be supported by “precise” 
justifications so that the laws may be “tailored to solving the problem[s] which justif[y] 
[their] existence”).  Another approach to mandating benefits for PrEP treatment at the state 
level would be amending existing mandates requiring insurers to cover HIV medication 
for the treatment of HIV infection by inserting language that would require insurers to 
cover HIV medication for the prevention of HIV.  See, e.g., WIS. STAT. § 632.895(9) 
(2014); OFFICE OF THE COMM’R OF INS., STATE OF WIS., PI-019, FACT SHEET ON MANDATED 
BENEFITS IN HEALTH INSURANCE POLICIES 5 (2012), http://oci.wi.gov/pub_list/pi-019.pdf 
[http://perma.cc/88XL-QRTD]. 
 324.  See Monahan, supra note 323, at 133. 
 325.  See id. at 136. 
 326.  See id. at 139. 
 327.  See id. at 200. 
328.  A financial analysis of the costs and benefits of a PrEP mandate is beyond the 
scope of this Article. 
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patients and providers about HIV risk, which may help eradicate PrEP-
related stigma.  It would also mitigate, at the state level, the prior authorization 
and medical necessity issues that PrEP may face in the future.  However, 
those seeking a mandated benefit law for PrEP will need to answer a 
number of questions.  What states should proponents target?329  Are there 
not incentives in the system for insurers to cover oral PrEP if it is truly 
beneficial?  Is it economically feasible?  Would a PrEP mandate lead to 
an increase in consumer costs across the plan because premiums could 
increase?  Would a PrEP mandate lead to reduction or abandonment of 
coverage by employers?  Would a PrEP mandate be sustainable in today’s 
political climate? 
In addition, proponents of mandated benefits for PrEP will also need to 
determine whether religious exemptions are necessary after the U.S. 
Supreme Court’s Burwell v. Hobby Lobby ruling, in which the Court 
sustained a free exercise challenge to an HHS oral contraceptive mandate 
that did not contain such an exemption.330  Could a religiously affiliated 
insurance issuer refuse to comply with a PrEP mandate by arguing that 
requiring coverage substantially burdens the free exercise of religion?  As 
the insurer in Hobby Lobby successfully argued in the context of birth 
control, religiously affiliated insurers could argue that requiring them to 
cover PrEP makes them complicit in conduct, such as MSM intercourse 
or intravenous drug use, that their religion proscribes.  Although a substantive 
analysis of the Hobby Lobby decision and its potential effect on HIV 
prevention efforts is beyond the scope of this Article, the decision does 
suggest that if there is an important public health goal, such as eradicating 
HIV/AIDS, that cannot be achieved through a less restrictive means other 
 329.  Those preparing to seek a mandated benefit for PrEP should focus on states that 
have (1) moved progressively on mandated benefit laws in the past, and (2) high rates of 
HIV incidence.  As of 2011, states with the highest HIV incidence were California (5965, 
11.9%), Florida (5394,10.8%), Texas (5044, 10.1%), New York (4944, 9.9%), and 
Georgia (2520, 5.0%).  The HIV/AIDS Epidemic in the United States, KAISER FAM. FOUND.
(Apr. 7, 2014), http://kff.org/hivaids/fact-sheet/the-hivaids-epidemic-in-the-united-states 
[http://perma.cc/4T9S-AVU9].  As of 2002, Maryland had the most mandated benefit laws 
(52), then California (45), then Texas (41).  Laugesen, supra note 313, at 1089.  Northeastern 
states tend to mandate more preventive services than other states.  MARIS A. BONDI &
MOLLY E. FRENCH, P’SHIP FOR PREVENTION, PREVENTIVE SERVICES: HELPING STATES
IMPROVE MANDATES 4 (2002), www.prevent.org/downloadStart.aspx?id=29 [http://perma. 
cc/B7U9-3R99]. 
 330.  Burwell v. Hobby Lobby Stores, Inc., 134 S. Ct. 2751, 2779 (2014); see also 
Baume, supra note 229 (noting that “[i]n the wake of the Hobby Lobby ruling, gay men 
may be vulnerable to employers who would attempt to block access to HIV drugs” for 
religious purposes). 
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than mandating coverage without religious exemptions, then such a 
mandate need not contain a religious exemption.331 
V.  CONCLUSION 
HIV PrEP is not a “magic pill” to prevent HIV infection.  However, 
even as an interim solution on the road to a vaccine and a cure, PrEP has 
remarkable potential—to arrest the increase in HIV incidence, to mitigate 
the effects of condom decline, and to eliminate the omnipresent 
prevention fatigue among high-risk communities. 
As PrEP advocates continue efforts to scale up utilization, a number of 
challenges follow them.  PrEP stigma continues at the self-imposed, 
individual, and institutional levels.  In addition, PrEP advocates are working 
to modernize a healthcare system that developed its approach to HIV 
prevention during the 1980s and 1990s and that does not yet have the 
scaffolding to provide efficient and affordable access to this new 
prevention modality.  As advocates work to remove accessibility barriers, 
they should not ignore the possibility of benefit denials.  These acceptability 
and accessibility challenges must be approached from multiple angles to 
achieve greater, sustainable utilization. 
One solution, though there are certainly more, is health content and 
utilization review regulation.  Governmental action requiring insurers to 
cover PrEP and help streamline the barriers to access is an option that 
would thrust PrEP into the mainstream, make it easier to obtain, and 
provide an economic incentive for members of high-risk groups to 
actually obtain it.  Of course, analysis of the economic feasibility of these 
proposals is needed, as is additional scholarship brainstorming other post-
health reform law and policy solutions to eliminating acceptability and 
accessibility hurdles to PrEP implementation. 
Nonetheless, the government has an obligation to sustain the new 
dynamism in HIV prevention discourse brought about by oral PrEP.  PrEP 
has injected new energy into the fight against HIV, which incidence we 
desperately need to reduce.  High-risk communities are engaged in a 
 331.  See Hobby Lobby, 134 S. Ct. at 2783 (“Our decision should not be understood 
to hold that an insurance-coverage mandate must necessarily fall if it conflicts with an 
employer’s religious beliefs.  Other coverage requirements, such as immunizations, may 
be supported by different interests (for example, the need to combat the spread of 
infectious diseases) and may involve different arguments about the least restrictive means 
of providing them.”). 
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vigorous and productive debate about PrEP in a way they have never 
engaged in HIV prevention before—on social media, in public gathering 
spaces, at rallies, in the doctor’s office, among friends, and in the 
bedroom.  In the words of PrEP advocate Jim Pickett: “PrEP gives us an 
entry point to talk about [condomless sex] in a way that’s helpful.  We can 
talk about effectiveness and reframe condoms.  We can reframe how we 
talk about protection and safer sex.”332  Indeed, PrEP has actually 
increased at-risk individuals’ eagerness to get involved in public health 
issues.  Moreover, PrEP has the potential to give at-risk individuals more 
control over and more investment in their health.333  Our government must 
ensure that this revolution continues. 
 332.  S.F. AIDS FOUND., supra note 130, at 10. 
 333.  See id. (“PrEP is a tool that empowers individuals to be proactive, take control, 
and plan ahead . . . .”). 
